1
|
Akhoundi M, Mathieu A, Hannachi W, Nasrallah J, Quezel G, Blaizot R, Blanchet D, Ben Romdhane H, Epelboin L, Izri A. Morphological and Molecular Characterizations of Cochliomyia hominivorax (Diptera: Calliphoridae) Larvae Responsible for Wound Myiasis in French Guiana. Diagnostics (Basel) 2023; 13:2575. [PMID: 37568937 PMCID: PMC10416906 DOI: 10.3390/diagnostics13152575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 07/25/2023] [Accepted: 07/27/2023] [Indexed: 08/13/2023] Open
Abstract
Myiasis is an ectoparasitic infection caused by the larvae of true flies (Diptera). We came across a rather rare case of myiasis in an immunocompetent 34-year-old man from French Guiana with advanced wound myiasis masquerading as cavitary myiasis and a history of cholesteatoma surgery in the left ear. The Diptera larvae responsible for the disease were isolated and identified using morphological and molecular approaches as Cochliomyia hominivorax. We underline the importance of this parasitosis as the second case of myiasis caused by C. hominivorax and the first case of wound myiasis in this overseas department of France and its incidence in pre-urban areas of the capital, Cayenne, in South America.
Collapse
Affiliation(s)
- Mohammad Akhoundi
- Parasitology-Mycology Department, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, 93000 Bobigny, France
| | - Alexandre Mathieu
- Groupe d’Étude et de Protection des Oiseaux en Guyane, Rémire-Montjoly 97354, French Guiana
| | - Wajih Hannachi
- ENT Department, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne 97306, French Guiana
| | - Jade Nasrallah
- Parasitology-Mycology Department, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, 93000 Bobigny, France
| | - Guillaume Quezel
- Infectious and Tropical Diseases Unit, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne 97306, French Guiana
| | - Romain Blaizot
- Department of Dermatology, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne 97306, French Guiana
| | - Denis Blanchet
- Parasitology Mycology Universitary Laboratory, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne 97306, French Guiana
| | | | - Loïc Epelboin
- Infectious and Tropical Diseases Unit, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne 97306, French Guiana
- Centre d’Investigation Clinique Antilles Guyane CIC Inserm 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne 97306, French Guiana
| | - Arezki Izri
- Parasitology-Mycology Department, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, 93000 Bobigny, France
- Unité des Virus Émergents (UVE: Aix-Marseille Université-IRD 190-Inserm 1207-IHU Méditerranée Infection), 13005 Marseille, France
| |
Collapse
|
2
|
Rolland T, Cliquet F, Anney RJL, Moreau C, Traut N, Mathieu A, Huguet G, Duan J, Warrier V, Portalier S, Dry L, Leblond CS, Douard E, Amsellem F, Malesys S, Maruani A, Toro R, Børglum AD, Grove J, Baron-Cohen S, Packer A, Chung WK, Jacquemont S, Delorme R, Bourgeron T. Phenotypic effects of genetic variants associated with autism. Nat Med 2023; 29:1671-1680. [PMID: 37365347 PMCID: PMC10353945 DOI: 10.1038/s41591-023-02408-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Accepted: 05/19/2023] [Indexed: 06/28/2023]
Abstract
While over 100 genes have been associated with autism, little is known about the prevalence of variants affecting them in individuals without a diagnosis of autism. Nor do we fully appreciate the phenotypic diversity beyond the formal autism diagnosis. Based on data from more than 13,000 individuals with autism and 210,000 undiagnosed individuals, we estimated the odds ratios for autism associated to rare loss-of-function (LoF) variants in 185 genes associated with autism, alongside 2,492 genes displaying intolerance to LoF variants. In contrast to autism-centric approaches, we investigated the correlates of these variants in individuals without a diagnosis of autism. We show that these variants are associated with a small but significant decrease in fluid intelligence, qualification level and income and an increase in metrics related to material deprivation. These effects were larger for autism-associated genes than in other LoF-intolerant genes. Using brain imaging data from 21,040 individuals from the UK Biobank, we could not detect significant differences in the overall brain anatomy between LoF carriers and non-carriers. Our results highlight the importance of studying the effect of the genetic variants beyond categorical diagnosis and the need for more research to understand the association between these variants and sociodemographic factors, to best support individuals carrying these variants.
Collapse
Affiliation(s)
- Thomas Rolland
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France.
| | - Freddy Cliquet
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France
| | - Richard J L Anney
- Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
| | - Clara Moreau
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France
| | - Nicolas Traut
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France
- Center for Research and Interdisciplinarity (CRI), Université Paris Descartes, Paris, France
| | - Alexandre Mathieu
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France
| | - Guillaume Huguet
- Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine, Montréal, Québec, Canada
| | - Jinjie Duan
- The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark
- Department of Biomedicine and the iSEQ Centre, Aarhus University, Aarhus, Denmark
- Center for Genomics and Personalized Medicine, Aarhus, Denmark
| | - Varun Warrier
- Autism Research Centre, Department of Psychiatry, University of Cambridge, Cambridge, UK
| | - Swan Portalier
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France
| | - Louise Dry
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France
| | - Claire S Leblond
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France
| | - Elise Douard
- Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine, Montréal, Québec, Canada
- Département de Pédiatrie, Université de Montréal, Montréal, Québec, Canada
| | - Frédérique Amsellem
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France
- Department of Child and Adolescent Psychiatry, Robert Debré Hospital, APHP, Paris, France
| | - Simon Malesys
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France
| | - Anna Maruani
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France
- Department of Child and Adolescent Psychiatry, Robert Debré Hospital, APHP, Paris, France
| | - Roberto Toro
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France
- Center for Research and Interdisciplinarity (CRI), Université Paris Descartes, Paris, France
| | - Anders D Børglum
- The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark
- Department of Biomedicine and the iSEQ Centre, Aarhus University, Aarhus, Denmark
- Center for Genomics and Personalized Medicine, Aarhus, Denmark
| | - Jakob Grove
- The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark
- Department of Biomedicine and the iSEQ Centre, Aarhus University, Aarhus, Denmark
- Center for Genomics and Personalized Medicine, Aarhus, Denmark
- Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark
| | - Simon Baron-Cohen
- Autism Research Centre, Department of Psychiatry, University of Cambridge, Cambridge, UK
| | | | - Wendy K Chung
- Simons Foundation, New York, NY, USA
- Department of Pediatrics, Columbia University Medical Center, New York, NY, USA
| | - Sébastien Jacquemont
- Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine, Montréal, Québec, Canada
- Département de Pédiatrie, Université de Montréal, Montréal, Québec, Canada
| | - Richard Delorme
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France
- Department of Child and Adolescent Psychiatry, Robert Debré Hospital, APHP, Paris, France
| | - Thomas Bourgeron
- Human Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, IUF, Université Paris Cité, Paris, France.
| |
Collapse
|
3
|
Vitrac A, Leblond CS, Rolland T, Cliquet F, Mathieu A, Maruani A, Delorme R, Schön M, Grabrucker AM, van Ravenswaaij-Arts C, Phelan K, Tabet AC, Bourgeron T. Dissecting the 22q13 region to explore the genetic and phenotypic diversity of patients with Phelan-McDermid syndrome. Eur J Med Genet 2023; 66:104732. [PMID: 36822569 DOI: 10.1016/j.ejmg.2023.104732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 02/14/2023] [Accepted: 02/19/2023] [Indexed: 02/25/2023]
Abstract
SHANK3-related Phelan-McDermid syndrome (PMS) is caused by a loss of the distal part of chromosome 22, including SHANK3, or by a pathological SHANK3 variant. There is an important genetic and phenotypic diversity among patients who can present with developmental delay, language impairments, autism, epilepsy, and other symptoms. SHANK3, encoding a synaptic scaffolding protein, is deleted in the majority of patients with PMS and is considered a major gene involved in the neurological impairments of the patients. However, differences in deletion size can influence clinical features, and in some rare cases, deletions at the 22q13 locus in individuals with SHANK3-unrelated PMS do not encompass SHANK3. These individuals with SHANK3-unrelated PMS still display a PMS-like phenotype. This suggests the participation of other 22q13 genes in the pathogenesis of PMS. Here, we review the biological function and potential implication in PMS symptoms of 110 genes located in the 22q13 region, focusing on 35 genes with evidence for association with neurodevelopmental disorders, including 13 genes for epilepsy and 11 genes for microcephaly and/or macrocephaly. Our review is restricted to the 22q13 region, but future large-scale studies using whole genome sequencing and deep-phenotyping are warranted to develop predictive models of clinical trajectories and to target specific medical and educational care for each individual with PMS.
Collapse
Affiliation(s)
- Aline Vitrac
- Génétique Humaine et Fonctions Cognitives, Institut Pasteur, UMR3571 CNRS, Université de Paris Cité, IUF, 75015, Paris, France.
| | - Claire S Leblond
- Génétique Humaine et Fonctions Cognitives, Institut Pasteur, UMR3571 CNRS, Université de Paris Cité, IUF, 75015, Paris, France
| | - Thomas Rolland
- Génétique Humaine et Fonctions Cognitives, Institut Pasteur, UMR3571 CNRS, Université de Paris Cité, IUF, 75015, Paris, France
| | - Freddy Cliquet
- Génétique Humaine et Fonctions Cognitives, Institut Pasteur, UMR3571 CNRS, Université de Paris Cité, IUF, 75015, Paris, France
| | - Alexandre Mathieu
- Génétique Humaine et Fonctions Cognitives, Institut Pasteur, UMR3571 CNRS, Université de Paris Cité, IUF, 75015, Paris, France
| | - Anna Maruani
- Department of Child and Adolescent Psychiatry, Hôpital Robert Debré, APHP, Paris, France
| | - Richard Delorme
- Department of Child and Adolescent Psychiatry, Hôpital Robert Debré, APHP, Paris, France
| | - Michael Schön
- Institute for Anatomy and Cell Biology, Ulm University, Ulm, Germany
| | - Andreas M Grabrucker
- Bernal Institute, University of Limerick, Limerick, Ireland; Dept. of Biological Sciences, University of Limerick, Limerick, Ireland; Health Research Institute HRI, University of Limerick, Limerick, Ireland
| | - Conny van Ravenswaaij-Arts
- University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, Netherlands
| | - Katy Phelan
- Genetics Laboratory, Florida Cancer Specialists & Research Institute, Fort Myers, FL, 33916, USA
| | | | - Thomas Bourgeron
- Génétique Humaine et Fonctions Cognitives, Institut Pasteur, UMR3571 CNRS, Université de Paris Cité, IUF, 75015, Paris, France.
| |
Collapse
|
4
|
Ravry B, Mathieu A, Bernard F, Demoisson F. Atomization regime observation and characterization of an atomized pure zinc rod during centrifugal atomization using a LASER beam. POWDER TECHNOL 2023. [DOI: 10.1016/j.powtec.2022.118139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
|
5
|
Mathieu A, Chan H, Coste V, Dutheil C. Scleritis and choroidal granuloma in a young patient with sarcoidosis. J Fr Ophtalmol 2022; 45:e446-e449. [DOI: 10.1016/j.jfo.2022.03.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 03/29/2022] [Accepted: 03/31/2022] [Indexed: 11/26/2022]
|
6
|
Gatto M, Depascale R, Tincani A, Emmi G, Scarpato S, Conti F, Govoni M, Mosca M, Gerosa M, Bozzolo E, Canti V, Gabrielli A, Gremese E, De Vita S, Ciccia F, Salvarani C, Rossini M, Faggioli P, Laria A, De Paulis A, Gerli R, Brunetta E, Mathieu A, Selmi C, De Angelis R, Negrini S, Zen M, Doria A, Iaccarino L. AB0441 PREDICTORS OF CLASI RESPONSE OVER TIME IN A MULTICENTRIC REAL LIFE COHORT OF SLE PATIENTS TREATED WITH BELIMUMAB. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundOver 80% of patients affected with SLE experience skin involvement. The anti-BLyS drug belimumab was shown effective in ameliorating mucocutaneous SLE manifestations in clinical trials and real-life studies. Cutaneous response is quantified through the CLASI (cutaneous lupus erythematosus area and severity index). Clinically relevant improvements are defined as decreases of ≥50% (CLASI50) or 70% (CLASI70) from baseline values.ObjectivesTo assess rates and predictors of CLASI50 and CLASI70 in the Berliss multicentric SLE cohort1 of patients treated with belimumab.MethodsBaseline and ongoing features of patients with baseline active skin involvement (CLASI>0) were assessed in relationship to the chosen outcomes CLASI50 and CLASI70 at 24 and 52 weeks. A subanalysis on patients with CLASI≥5 was as well conducted. Logistic regression was employed to identify predictors of response.Results172 patients displayed skin involvement at baseline (CLASI>0). Of those, 124 displayed at least a 12-month-follow-up and were included in the analysis. Seventy-seven (62.1%) patients reached CLASI50 at 24 weeks and 91 (77.8%) at 52 weeks; 87 (70.2%) reached CLASI70 at 24 and 99 (79.8%) at 52 weeks. Baseline predictors of CLASI50 at 24 weeks were CLASI-damage (CLASI-d) (OR [95%CI], p; 0.79 [0.65-0.98] 0.03) and disease duration (0.93[0.86-0.99], 0.011). No baseline predictors of CLASI70 at 24 weeks emerged, however having achieved a CLASI50 response at 24 weeks portended CLASI50 and 70 response through week 52 (p<0.01, Table 1). In the subgroup of patients with CLASI≥5, longer disease and increased CLASI-d at baseline confirmed as negative predictors of CLASI50 at 24 weeks. In this subset, use of antimalarials and active smoking at baseline predicted CLASI70 at 24 weeks (Table 1).Table 1.Predictors of CLASI-A Response at Week 24 and 52 by Baseline CLASI-A at 50% and 70% Response ThresholdsTimepointOutcomeVariableOR[95%CI] pCLASI>024 weeksCLASI50CLASI-d0.79 [0.65-0.98] 0.030Disease duration0.93[0.86-0.99], 0.011CLASI70CLASI-d0.93 [0.74-1.16], 0.51Disease duration0.97 [0.97-1.02], 0.1852 weeksCLASI50CLASI50 at 24 weeks14.3[4.88-44.42], <0.001CLASI70CLASI50 at 24 weeks6.22 [2.00-19.34], 0.002CLASI≥524 weeksCLASI50CLASI-d0.72 [0.53-0.98], 0.037Disease duration0.93 [0.66-1.00], 0.071CLASI70Antimalarials6.61 [1.20-36.29] 0.032Smoking0.15 [0.03-0.83], 0.03452 weeksCLASI50CLASI50 at 24 weeks22.0 [2.47-196.05], 0.006CLASI70CLASI50 at 24 weeks1.24 [0.06-25.08], 0.88CLASI, cutaneous lupus erythematosus area and severity index; CLASI-d, CLASI damage; CLASI50 and CLASI70: decrease ≥50% or ≥70% in CLASI from baseline. OR and 95%CIs are estimated using a logistic regression model with stratification factors as covariates (SLEDAI-2K at baseline, baseline prednisone dosage).ConclusionEarlier use of belimumab favors achievement of skin response among SLE patients and attainment of a prompt response predicts further response. Use of antimalarials reinforces while smoking hampers a more profound CLASI improvement over time.References:[1]Gatto M, et al. Arthritis Rheumatol. 2020 Aug;72(8):1314-1324Disclosure of InterestsMariele Gatto Speakers bureau: GSK, Grant/research support from: GSK, Roberto Depascale: None declared, Angela Tincani: None declared, Giacomo Emmi: None declared, Salvatore Scarpato: None declared, Fabrizio Conti: None declared, Marcello Govoni: None declared, Marta Mosca: None declared, Maria Gerosa: None declared, Enrica Bozzolo: None declared, Valentina Canti: None declared, Armando Gabrielli: None declared, Elisa Gremese: None declared, Salvatore De Vita: None declared, francesco ciccia: None declared, Carlo Salvarani: None declared, Maurizio Rossini: None declared, Paola Faggioli: None declared, Antonella Laria: None declared, Amato De Paulis: None declared, Roberto Gerli: None declared, Enrico Brunetta: None declared, Alessandro Mathieu: None declared, Carlo Selmi: None declared, Rossella De Angelis: None declared, Simone Negrini: None declared, Margherita Zen: None declared, Andrea Doria Speakers bureau: GSK, Eli Lilly, Roche, Grant/research support from: GSK, Luca Iaccarino Speakers bureau: GSK, Grant/research support from: GSK
Collapse
|
7
|
Chessa E, Piga M, Porcu M, Pintus E, Perra A, Serafini C, Floris A, Congia M, Angioni MM, Carta MG, Saba L, Mathieu A, Cauli A. POS0787 THE EFFECT OF ANTI-RIBOSOMAL-P AND ANTI-NR2 ANTIBODIES ON FUNCTIONAL BRAIN MRI NETWORKS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH DEPRESSION AND BEHAVIORAL COGNITIVE DISORDERS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.5021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundCognitive dysfunction (CD) and mood disorders (MD) are among the most frequent neuropsychiatric (NP) events in Systemic Lupus Erythematosus (SLE), but their pathogenesis has not been clarified yet. Until now, an unquestionable correlation between the presence of specific autoantibodies, brain alterations and the presence of CDs and MDs in SLE is lacking.ObjectivesThe primary aim of the study was to explore the effects of anti-NR2 (anti-DWEYS) and anti-ribosomal-P (anti-P) antibodies on CDs and MDs and their relation with functional brain connectivity in patients affected by SLE.MethodsA cross-sectional study was conducted, between April 2019 and February 2020, including adult patients who fulfilled the ACR/EULAR 2019 SLE criteria.Demographics, ongoing medications, SLEDAI and SLICC/Damage Index were recorded. Serum level quantification for anti-P (normal values <18 U/ml) and anti-NR2 (normal values <0.5 OD) antibodies were performed using an ELISA. A battery of neuropsychological testing was interpreted by a neuropsychologist, exploring cognitive domains, depression and quality of life. A resting-state functional connectivity (rs-fc) MRI analysis was performed within 2 weeks since the neuropsychological status assessments. Two region of interest to region of interest (ROI-to-ROI) analyses with the graph theory was performed.ResultsThirty-three SLE patients (9% male) were enrolled, mean age 43.5 (+-14) years, and median disease duration of 10.4 years (IQR 2.9-25.4) (Table 1). Anti-P were positive (range 0-255 U/ml) in 6 patients (18.2%) and anti-DWEYS (range 0-1.8 OD) in 14 (42.4%). Nineteen out of 33 patients (57.6%) showed at least a cognitive test alteration, but no significant association with antibodies was found. Depression was found in 14 (42.4%) patients using the Center for Epidemiologic Studies Depression Scale (CES-D) as screening instrument. In multiple regression backward models, after correction for age, disease duration, SLEDAI and SDI, the CES-D showed an independent association with anti-P titre (β= 0.32 per U/ml; p=0.049) and prednisone daily dose (β=0.38 per mg/day; p=0.023). The rs-fc MRI analysis revealed a statistically significant association between the titre of anti-P and many altered properties of the brain ROIs (Figure 1), but no effects of PDN daily dose on specific cerebral networks.Table 1.Demographic and clinical characteristics of the patients in total, Legend: PDN: Prednisone; LLDAS: Lupus Low Disease Activity State; OD: Optical densityDemographic and clinical characteristics of the participants(N=33)Age, years mean (DS)43.5 (14.0)Gender (M, %)3 (9%)Disease duration, months median (IQR)124.4 (34.7-305)SLEDAI-2k mediane (IQR)4 (0-14)Dose PDN mg/daily median (IQR)6.4 (3.8-13.5)LLDAS N, %12 (36,4%)SLICC-DI mediane (IQR)0 (0-1)Ongoing treatment25 (75.8%)Hydroxychloroquine30 (90.9%)Immunosuppressive9 (27.3%)BiologicsEducation less than 8 years13 (39.4%)Anti-Rib-P N, %6 (18.2%)Anti-Rib-P (U/ml) mean (DS)10.9 (5.7-13.3)Anti-DWEYS N, %14 (42.4%)Anti-DWEYS (OD) mean (DS)0.4 (0.25-0.67)Anti-phospholipids N, %11 (33.3%)anti-dsDNA N, %18 (54.5%)anti-dsDNA Titre mediane (IQR)22.5 (2.9-74.5)Figure 1.Results of rs-fc MR Analysis 1 (effects of Anti-rib-P titre) on cerebral networks. The regions with decreased and increased property are shown in blue and red nodes, respectively (p< 0.01). The node size represents the significance of the between-group differences in the nodal degree.ConclusionAnti-P antibodies are associated with depressive symptoms and changes of brain network properties in SLE patients, which add knowledge on their pathogenetic effect.Disclosure of InterestsNone declared
Collapse
|
8
|
Laconi R, Floris A, Espinosa G, Lopalco G, Serpa Pinto L, Kougkas N, Sota J, Lo Monaco A, Govoni M, Cantarini L, Bertsias G, Correia J, Iannone F, Cervera R, Vasconcelos C, Mathieu A, Cauli A, Piga M. AB0631 Impact of Behçet’s Syndrome on work activity and productivity: results from a sub-analysis of the BODI Project cohort. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundBehçet’s Syndrome (BS) is a multisystem recurring inflammatory disorder characterised by a wide spectrum of clinical manifestations, which can vary from limited mucocutaneous lesions up to severe and even life-threatening events.ObjectivesTo evaluate the impact of BS on the patients’ work activity and productivity.MethodsA sub-cohort of 148 patients from the original Behçet’s syndrome Overall Damage Index (BODI) Project study was enrolled. The Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire was administered. Demographics, disease duration, comorbidity, major organ involvement, ongoing therapy, Behçet's Disease Current Activity Form (BDCAF), Physician Global Assessment (PGA), Patient Global Assessment (PtGA), and the BODI were recorded. Multiple regression models were built to investigate the independent effect of BS features on WPAI.ResultsOverall, 97 (65.6%) out of 148 patients who completed the WPAI:GH questionnaire resulted working for pay; 22 out of 97 (27.8%) patients reported missing work in the past week due to their health, accounting for a mean (SD) of 34.4% (17.8) of their working time (absenteeism). The only factor significantly associated with absenteeism in multivariate analysis was the presence of ocular damage, as assessed by the BODI (β 0.255, p = 0.027).Although 93 patients reported that they worked in the previous week, mean 27.3% (30.7) of their actual work productivity was impaired due to their health problem (presenteeism), with only 37 (38.5%) patients reporting no such loss. Factors associated with work impairment were female gender (β 0.319, p = 0.001), higher PtGA (β 0.298, p = 0.002), and an increased BODI score in the last 2 years follow-up (β 0.212 for one-point increased BODI score, p = 0.024).Finally, 99 (66.9%) of the total 148 patients complained of a daily activity impairment, reporting that a mean of 33.3% (30.6) of their regular daily activities had been prevented due to their health problems. Factors significantly associated with patients’ daily activity impairment were younger age at enrolment (β 0.187, p = 0.021), higher BDCAF disease activity (β 0.235, p = 0.002) and fibromyalgia (β 0.324, p = 0.033).ConclusionBS can lead to missing work time and significantly affect both the patient’s work productivity and daily activities. Active disease seems to be one of the major determinants together with a higher burden of damage and the association of some specific comorbidities, such as fibromyalgia.Table 1.WPAI:GH questionnaire resultsVariablesn°Mean (SD)All patients148Patients working for pay97Percent work time missed due to health977.9 (21.7)Percent work time missed due to health (patients with missed time >0) *2234.4 (17.8)Patients who actually worked in the past seven days**93Percent impairment while working due to health9327.3 (30.7)Percent impairment while working due to health (pts with % impairment while working > 0) ***5645.4 (27.2)Percent activity impairment due to health14833.3 (30.6)Percent activity impairment due to health (those with % activity impairment >0)9949.8 (23.9)* Patients working for pay who missed at least on hour of work, 22/97 = 22.7%.** Patients working for pay, but who worked for > 0 hours in the last week = 93/97*** Patients with impairment while working > 0 among patients who actually worked in the previous 7 day = 56/93.Disclosure of InterestsNone declared
Collapse
|
9
|
Floris A, Laconi R, Espinosa G, Lopalco G, Serpa Pinto L, Kougkas N, Sota J, Lo Monaco A, Govoni M, Cantarini L, Bertsias G, Correia J, Iannone F, Cervera R, Vasconcelos C, Mathieu A, Cauli A, Piga M. AB0636 Relationship between organ damage and impairment of health-related quality of life in patients with Behçet’s Syndrome: results from a longitudinal extension of the BODI Project. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPreventing accrual of organ damage represents a primary goal in the treatment of Behçet’s Syndrome (BS), as it may result in impairment of other outcomes, including the health-related quality of life (HR-QoL).ObjectivesThe objective of this study was to investigate whether the recent accrual of organ damage, rather than its extent at a single time point, correlate with an impairment of the HR-QoL.MethodsA sub-analysis of data from patients recruited in the longitudinal phase of the BODI Project validation cohort was performed. The HR-QoL and damage were measured by the Short-form 36 questionnaire (SF-36) and the BS Overall Damage Index (BODI), respectively, at the baseline visit and at a follow-up (FU) 24 ±3 months later. Then the possible increase of damage over FU was assessed by calculating the difference between the BODI score (Δ-BODI) in the two visits. Then, the relationship between the Δ-BODI and the individual and summary domains of the SF-36 was analysed by building multivariate regression models, including age, gender, concomitant fibromyalgia and/or depression, current disease activity as assessed by the BDCAF, as confounding variables.ResultsFrom the BODI validation cohort, 147 patients were recruitable for this sub-analysis;73 (49.8%) were males. The mean (SD) age and disease duration at enrolment were, respectively, 46.2 (12.4) and 13.4 (10.1) years. BODI score did not influence the SF-36 domains assessed at the baseline visit. In contrast, a significant correlation was recorded between the Δ-BODI and the following SF-36 domains: physical function (PF) (β -0.158 for 1 unit increase in BODI score, p 0.025), role physical (RP) (β -0.150, p 0.044), general health (GH) (β -0.199, p 0.004), role emotional (RE) (β -0.180, p 0.001), mental health (MH) (β -0.244, p 0.001), and the mental components summary (MCS) (-0.203, p 0.008)(Figure 1). Gender, age, fibromyalgia and disease activity were also confirmed to significantly influence HR-QoL (Table 1).Table 1.Multiple regression for the assessment of the relationship between Δ-BODI and SF-36 domainsΔ-BODIMaleAgeFBMDPRBDCAFPhysical function (PF)-0.158 (p 0.025)0.180 (p 0.010)-0.299 (p<0.001)-0.358 (p<0.001)-- (p 0.552)-0.141 (p 0.044)Role-physical (RP)-0.150 (p 0.044)0.154 (p 0.039)-0.212 (p 0.001)-0.278 (p<0.001)-- (0.086)-0.251 (p<0.001)Body-pain (BP)-- 0.8680.266 (p<0.001)-0.286 (p<0.001)-0.276 (p<0.001)-- (p 0.799)-262 (p<0.001)General health (GH)-0.199 (p 0.004)0.187 (p 0.010)-- (0.136)-0.296 (p<0.001)-- (0.861)-0.352 (p<0.001)Vitality (VT)-- (p 0.868)0.238 (p 0.001)-0.178 (p 0.008)-0.213 (0.002)-- (p 0.855)-0.371 (p<0.001)Social function (SF)-- (p 0.239)0.299 (p 0.004)-0.166 (p 0.024)-0.242 (p 0.001)-- (0.831)-0.202 (p 0.010)Role emotional (RE)-0.180 0.003)0.158 (p 0.047)-0.157 (p 0.048)-0.233 (p 0.003)-- (0.531)-0.191 (p 0.016)Mental health (MH)-0.244 (p 0.001)-- (p 0.142)-- (p 0.142)-0.292 (p<0.001)-- (p 0.073)-0.254 (p 0.001)Physical Component Summary (PCS)-- 0.1050.229 (p 0.001)-0.298 (p<0.001)-0.296 (p<0.001)-0.254 (p<0.001)Mental Component Summary (MCS)-0.203 (p 0.008)-- (p 0.068)-- (0.246)-0.255 (p 0.001)-- (0.122)-0.302 (p<0.001)FBM: fibromyalgia; DPR: depressionConclusionThe recent accrual of organ damage, rather than its extent assessed in a single visit, is associated with impairment of different aspects of heath related quality of life, especially those mental related. Such phenomenon is similar to that observed in other systemic rheumatic disease, may be due to coping mechanisms.Disclosure of InterestsNone declared
Collapse
|
10
|
Floris A, Laconi R, Espinosa G, Lopalco G, Serpa Pinto L, Kougkas N, Sota J, Lo Monaco A, Govoni M, Cantarini L, Bertsias G, Correia J, Iannone F, Cervera R, Vasconcelos C, Mathieu A, Cauli A, Piga M. AB0630 Assessment of organ damage accrual in Behçet's Syndrome over 2-year follow-up: results from the BODI Project longitudinal extension. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundPreventing accrual of organ damage is a major goal in the treatment of Behçet’s Syndrome (BS). The BS Overall Damage Index (BODI) is the first damage assessment tool developed and preliminarily validated for BS.ObjectivesTo assess the prevalence, extent, and determinants of organ damage accrual in the BODI validation cohort over 24 months of follow-up.MethodsOverall, 189 patients from the multicenter BODI cohort underwent a 24 ±3 months follow-up (FU) visit. Demographics, ongoing medication, Behçet’s Disease Current Activity Form (BDCAF) score, Physician (PGA) and Patient Global Assessment (PtGA) of disease activity, disease relapsing (defined by any treatment change due to increased disease activity), and the BODI score were recorded. Damage accrual was defined as any increase ≥1 in the BODI score between baseline and follow-up visit (Δ-BODI). Logistic regression models were built to identify factors associated with BODI damage accrual.ResultsThe mean age (standard deviation) at enrolment and the disease duration was 46.2 (12.1) and 10.8 (8.3) years, respectively, and 92/189 (48.7%) patients were males. During 24 months, 36 (19.0%) patients had an increase in the BODI score of at least 1 point (mean increase of 1.7 points). The BODI score increased from 1.6 (2.1) to 1.9 (2.1), with a mean Δ-BODI of 0.3 (0.8). Overall, 61 new BODI items of damage were recorded (Figure 1); 22 (34%) were steroid-related (diabetes, osteoporotic fractures, cataract). Factors independently associated with increased BODI score were longer glucocorticoids exposure (OR 1.01 per month, 95%CI 1.01-1.02, p<0.001), and occurrence of flares (OR 3.1, 95%CI 1.1-8.9, p = 0.035), whereas stable treatment with conventional and/or biologic immunosuppressants was negatively associated with an increase in the BODI score (OR 0.19, 95% 0.07-0.97, p <0.001) (Table 1).Table 1.Determinants of organ damage accrual over 2 years of follow-up.Univariate analysisMultivariate analysisCandidate determinantsΔ-BODI ≥1 (n 36)Δ-BODI = 0 (n 153)pOR (95%CI)pMales16 (44.4%)76 (49.7%)0.572Age at enrolment56.2 (42.9-62.0)46.6 (35.4-53.1)0.001----Disease duration12.9 (7.1-22.0)11.1 (5.4-21.2)0.483Major organ involv.22 (61.1%)72 (47.1%)0,129BDCAF at BL3 (0-5)2. (0-5)0.365BDCAF at FU visit3.0 (3-5)3 (0-7)0.188GC duration112 (26.0-147.0)24.0 (8.0-72.0)<0.0011.012 (1.006-1.018<0.001cIS or TNFì ever24 (66.7%)133 (86.9%)0.0040.194 (0.073-0.972)<0.001Relapse9 (25.0%)20 (13.1%)0.0703.093 (1.066-8.972)0.038BODI score at BL1.0 (0-2.0)1 (0-2)0.579Continuous variables are presented as median (IQR). Dichotomic variable are presented as n (%). BODI, Behçet’s Syndrome Overall Damage Index. FU, follow-up. cIS, conventional immunosuppressant. Δ-BODI increase of BODI score from baseline to the FU visit.ConclusionDespite the relatively high disease duration in the studied cohort, organ damage accrual was recorded in a relevant proportion of patients. BODI proved to capture the damage associated with major determinants such as inadequate control of disease activity and prolonged exposure to glucocorticoids.Disclosure of InterestsNone declared
Collapse
|
11
|
Mathieu A, Thiboutot Z, Ferreira V, Benoit P, Grandjean Lapierre S, HÉtu PO, Halwagi A. Voriconazole Sequestration During Extracorporeal Membrane Oxygenation for Invasive Lung Aspergillosis: A Case Report. ASAIO J 2022; 68:e56-e58. [PMID: 33788798 DOI: 10.1097/mat.0000000000001427] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
The increasing use of extracorporeal membrane oxygenation (ECMO) in critical care introduces new challenges with medication dosing. Voriconazole, a commonly used antifungal and the first-choice agent for the treatment of invasive aspergillosis, is a poorly water-soluble and highly protein-bound drug. Significant sequestration in ECMO circuits can be expected; however, no specific dosing recommendations are available. We report on the therapeutic drug monitoring and clinical evolution of a patient treated with voriconazole for invasive pulmonary aspergillosis while receiving ECMO therapy. Voriconazole trough levels were persistently low (<1 µg/mL) after initiation of ECMO despite additional loading doses and dose increases. Voriconazole dose had to be increased to 6.5 mg/kg three times daily to obtain therapeutic trough levels. The inability to achieve therapeutic levels of voriconazole for a prolonged period (a minimum of 9 days) while undergoing ECMO therapy is believed to have been a significant contributing factor in the patient's fatal outcome. Therapeutic trough levels of voriconazole cannot be guaranteed with standard dosing in patients undergoing ECMO and much higher doses may be necessary. Empirical use of higher doses and/or combination therapy may be reasonable and frequent therapeutic drug monitoring is mandatory.
Collapse
Affiliation(s)
- Alexandre Mathieu
- From the Department of Pharmacy, Centre Hospitalier de l'Université de Montréal, 1051 Rue Sanguinet, Montréal, Québec, Canada
- Immunopathology Axis, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, 900 rue Saint-Denis, Montréal, Québec, Canada
| | - ZoÉ Thiboutot
- From the Department of Pharmacy, Centre Hospitalier de l'Université de Montréal, 1051 Rue Sanguinet, Montréal, Québec, Canada
- Innovation Hub Axis, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, 900 rue Saint-Denis, Montréal, Québec, Canada
| | - Victor Ferreira
- From the Department of Pharmacy, Centre Hospitalier de l'Université de Montréal, 1051 Rue Sanguinet, Montréal, Québec, Canada
| | - Patrick Benoit
- Microbiology, Infectious Diseases and Immunology Department, Université de Montréal, 2900 Boulevard Édouard Montpetit, Montréal, Québec, Canada
| | - Simon Grandjean Lapierre
- Immunopathology Axis, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, 900 rue Saint-Denis, Montréal, Québec, Canada
- Microbiology, Infectious Diseases and Immunology Department, Université de Montréal, 2900 Boulevard Édouard Montpetit, Montréal, Québec, Canada
| | - Pierre-Olivier HÉtu
- Department of Laboratory Medicine, Centre Hospitalier de l'Université de Montréal, 1000 rue Saint-Denis, Montréal, Québec, Canada
| | - Antoine Halwagi
- Department of Anesthesiology, Centre Hospitalier de l'Université de Montréal, 1000 rue Saint-Denis, Montréal, Québec, Canada
| |
Collapse
|
12
|
Ruiz I, Huard G, Fournier C, Bissonnette J, Castel H, Giard JM, Villeneuve JP, Fenyves D, Marleau D, Willems B, Corsilli D, Correal F, Ferreira V, Martel D, Mathieu A, Vincent C, Bilodeau M. A real-world experience of SARS-CoV-2 infection in a tertiary referral centre of Montréal: Unexpected low prevalence and low mortality. CanLivJ 2021; 4:391-400. [DOI: 10.3138/canlivj-2021-0022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 08/12/2021] [Accepted: 08/13/2021] [Indexed: 11/20/2022]
Abstract
BACKGROUND: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with chronic liver disease (CLD) and liver transplant (LT) recipients remains a concern. The aim of this study was to report the impact of coronavirus disease 2019 (COVID-19) infection among patients at the tertiary health care centre Centre hospitalier de l’Université de Montréal (CHUM) during the first wave of the SARS-CoV-2 pandemic. METHODS: This real-world, retrospective cohort included all patients admitted to our liver unit and/or seen as an outpatient with CLD with or without cirrhosis and/or LT recipients who tested positive to SARS-CoV-2 infection. Cases were considered positive as defined by the detection of SARS-CoV-2 by reverse-transcription polymerase chain reaction (RT-PCR) on nasopharyngeal swabs. RESULTS: Between April 1 and July 31, 2020, 5,637 were admitted to our liver unit and/or seen as outpatient. Among them, 42 were positive for SARS-CoV-2. Twenty-two patients had CLD without cirrhosis while 16 patients had cirrhosis at the time of the infection (13, 2, and 1 with Child–Pugh A, B, and C scores, respectively). Four were LT recipients. Overall, 15 of 42 patients (35.7%) were hospitalized; among them, 7 of 42 (16.7%) required respiratory support and 4 of 42 (9.5%) were transferred to the intensive care unit. Only 4 of 42 (9.5%) patients died: 2 with CLD without cirrhosis and 2 with CLD with cirrhosis. Overall survival was 90.5%. CONCLUSION: This real-world study demonstrates an unexpectedly low prevalence and low mortality in the context of SARS-CoV-2 infection among patients with CLD with or without cirrhosis and LT recipients.
Collapse
Affiliation(s)
- Isaac Ruiz
- Liver Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Geneviève Huard
- Liver Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Claire Fournier
- Liver Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Julien Bissonnette
- Liver Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Hélène Castel
- Liver Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Jeanne-Marie Giard
- Liver Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Jean-Pierre Villeneuve
- Liver Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Daphna Fenyves
- Liver Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Denis Marleau
- Liver Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Bernard Willems
- Liver Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Daniel Corsilli
- Intensive Care Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Florence Correal
- Pharmacy Department, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Victor Ferreira
- Pharmacy Department, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Dominic Martel
- Pharmacy Department, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Alexandre Mathieu
- Pharmacy Department, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Catherine Vincent
- Liver Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| | - Marc Bilodeau
- Liver Unit, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
| |
Collapse
|
13
|
Fredi M, Rizzo G, Andreoli L, Bacco B, Bertero T, Bortoluzzi A, Ceccarelli F, Cimaz R, Conigliaro P, Corradi F, De Vita S, DI Poi E, Elefante E, Emmi G, Gerosa M, Govoni M, Hoxha A, Lojacono A, Marrani E, Marozio L, Mathieu A, Mosca M, Melissa P, Picchi C, Piga M, Priori R, Ramoni V, Ruffatti A, Simonini G, Tani C, Tonello M, Trespidi L, Urban ML, Vezzoli M, Zatti S, Calza S, Brucato A, Franceschini F, Tincani A. POS0751 COMORBIDITY AND LONG-TERM OUTCOME IN PATIENTS WITH CONGENITAL HEART BLOCK: PRELIMINARY DATA OF THE ITALIAN REGISTRY ON THE IMMUNE-MEDIATED CONGENITAL HEART BLOCK. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Congenital heart block (CHB) is due to placental transfer of maternal anti-Ro/SSA autoantibodies to the fetus. The prevalence of CHB has been estimated as 1-2% in anti-Ro/SSA women while the recurrence rate is 16-19% (1). This condition is associated with a high rate of fetal/neonatal mortality and most of the cases requires pacemaker (PM) pacing. Given the rarity of CHB, limited data are available regarding the long-term follow-up of the offspring other than the cardiovascular complications.Objectives:The results of the Italian Registry of the autoimmune congenital heart block were recently described (2). A peculiarity of this cohort was that most of the mothers had an established diagnosis of systemic autoimmune disease at CHB detection, in contrast with other registries where CHB was mostly incidentally detected in healthy women. Here we report an update, with the preliminary data regarding the long-term outcome of patients with CHB, their unaffected siblings and health controls born from mothers positive for Ro/SSA.Methods:Data regarding demography, treatment, maternal, neonatal outcome, and follow-up were collected through an online electronic datasheet. A dedicated questionnaire was created with the aim to investigate general health, cardiovascular follow-up, and frequency of autoimmune diseases.Results:One-hundred and five cases of CHB in 99 patients were included from 1969 to December 2020. CHB was mostly detected in utero (97 cases, 92.3%) with 8 neonatal cases. Third degree CHB occurred in 71 cases (67.6%). Child mortality was observed in 29 (27.6%) cases: 20 in utero, 7 during neonatal period and 2 during childhood. Overall, a PM was implanted in 54 out of the 85 live births (63.5%). Then, our cohort was divided into 2 subgroups: pregnancy that occurred before (N=61) and after 2010 (N=44) with the aim to evaluate possible differences among the subgroups. Whereas mortality, PM, CHB degree were similar, CHB more frequently occurred in the last 10 years among Ro/SSA asymptomatic carriers than in the group of pregnancies before 2010 (53.6% vs 32.8%, p=0.038). Questionnaires from 14 surviving CHB cases, 8 unaffected siblings 12 controls born from mothers Ro/SSA positive were collected. Among CHB cases, 6 were males and 8 females, median age 12 years (range 6-28). All presented a third degree CHB, 10 required a neonatal PM pacing and one had an implantable ECG recorder. PM was substituted at least once in 9 patients, the oldest patient had to change it four times. No dilated cardiomyopathy occurred and most of the patients maintain an annual follow-up. Two cases of autoimmune diseases were registered among CHB cases, one idiopathic juvenile arthritis and one Cogan’s vasculitis, both born from mothers with Sjogren Syndrome. Four cases of neurodevelopmental disorders occurred: three cases of learning disabilities (one in each group) and one case of speech disorder in the sibling group. In addition, a CHB case presented a stress disorder linked to frequent hospitalizations.Conclusion:This registry is an ongoing project aiming at collecting all Italian CHB. Moreover, here we reported the preliminary data concerning the evaluation of long-term follow-up of CHB patients. Our data, even if need to be confirmed in larger cohort, seems reassuring: no differences were reported comparing CHB patients with unaffected siblings or controls.References:[1]Brito-Zéron et al. Nat Rev Rheumatol 2015;11:301-312.[2]Fredi M et al. Front Cardiovasc Med. 2019 Feb 28;6:11.Disclosure of Interests:None declared
Collapse
|
14
|
Ferreira V, Vincelette C, Mathieu A. Joint Efforts to Ensure Evidence-Based Decisions by Clinicians in Drug Adjustment for Chronic Liver Disease Populations. Hepatol Commun 2021; 5:713-714. [PMID: 33860128 PMCID: PMC8034572 DOI: 10.1002/hep4.1664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Victor Ferreira
- Department of PharmacyCentre Hospitalier de l'Université de MontréalMontréalQuébecCanada
| | - Christian Vincelette
- School of NursingFaculty of Medicine and Health SciencesUniversité de SherbrookeSherbrookeQuébecCanada
| | - Alexandre Mathieu
- Department of PharmacyCentre Hospitalier de l'Université de MontréalMontréalQuébecCanada.,Research CentreCentre hospitalier de l'université de MontréalMontréalQuébecCanada
| |
Collapse
|
15
|
Khazaka M, Laverdière J, Bouchard A, Ferreira V, Mathieu A. Identification of Possible Causative Agents in a Polymedicated Patient Presenting With Toxic Epidermal Necrolysis. J Pharm Pract 2020; 34:970-974. [PMID: 32588724 DOI: 10.1177/0897190020934295] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PURPOSE To present the pharmacological evaluation process in a case of a polymedicated patient presenting with toxic epidermal necrolysis (TEN). SUMMARY A 75-year-old Caucasian polymedicated woman had been treated for hip pain with nonsteroidal anti-inflammatory drugs and pregabalin in the months preceding the apparition of an expanding papulo-erythematous rash. She had also started using new medicated eye drops for glaucoma. She presented to the emergency department of a regional hospital where all of her medications were stopped. The patient was transferred and admitted to a tertiary-care teaching hospital's specialized burn unit for significant cutaneous detachment. It was estimated that 70% to 80% of the body surface area was affected. Skin biopsy showed keratinocyte necrosis with a partial detachment of the epidermis leading to a diagnosis of TEN. The reaction ceased to progress 2 days after the discontinuation of her medications. A complete reepithelialization was objectified after 10 days. A series of steps were followed by the hospital pharmacist to determine which drugs were the most probable culprits. A complete pharmacological history was obtained and a timeline for medication use in the 3 months preceding rash apparition was established. A review of the literature was done to determine the drugs' relationships to Steven-Johnson syndrome or TEN. Using the algorithm of drug causality for epidermal necrolysis (ALDEN) score, it was determined that naproxen, pregabalin, and brinzolamide-timolol drops were all possible culprits. CONCLUSION A systematic method for pharmacological evaluation of a polymedicated patient with TEN is presented. Naproxen, pregabalin, and brinzolamide-timolol drops were all retained as possible culprits.
Collapse
Affiliation(s)
- Michael Khazaka
- Department of Pharmacy, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada
| | - Jeanne Laverdière
- Department of Pharmacy, Centre Intégré de Santé et de Services Sociaux de la Montérégie-Est, Longueuil, Québec, Canada
| | - Audrey Bouchard
- Department of Pharmacy, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada
| | - Victor Ferreira
- Department of Pharmacy, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada
| | - Alexandre Mathieu
- Department of Pharmacy, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.,Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada
| |
Collapse
|
16
|
Fredi M, Cavazzana I, Ceribelli A, Lazzaroni MG, Barsotti S, Benucci M, Cavagna L, De Stefano L, Doria A, Emmi G, Fornaro M, Furini F, Gerli R, Giudizi MG, Govoni M, Ghirardello A, Iaccarino L, Iannone F, Infantino M, Mathieu A, Marasco E, Migliorini P, Palterer B, Parronchi P, Piga M, Pratesi F, Radice A, Selmi C, Riccieri V, Tampoia M, Zanframundo G, Tincani A, Franceschini F. FRI0239 ANTI-NXP2 ANTIBODIES: CLINICAL AND SEROLOGICAL ASSOCIATIONS IN A MULTICENTRIC ITALIAN STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:anti-NXP2 antibodies is considered a serological marker of dermatomyositis (DM), with calcinosis, severe myositis and, in some series, cancer. Historically, these associations have been detected with immunoprecipitation (IP), but in the last few years commercial lineblot (LB) assay have been released.Objectives:to analyze the clinical features associated to anti-NXP2 antibodies, including the onset of concomitant cancers, both with LB and homemade IPMethods:clinical and serological data from medical charts of 213 patients with a diagnosis of inflammatory miosidites without anti-NXP2 (NXP2-), followed-up by two third-level Centers, and 61 anti-NXP2+ patients from 10 Rheumatological centers were analyzed. Anti-myositis specific (MSA) and anti-myositis associated antibodies (MAA) were detected in single centers by LB (Euroimmun Autoimmune Inflammatory Myopathies 16 antigens). Anti-NXP2 was confirmed by protein and RNA IP, as previously described (1)Results:clinical diagnosis of anti-NXP2+ positive with LB were 42 DM, 11 PM, inclusion body myositis (IBM) 4, necrotizing myositis and overlap (OM) 1 each. Anti-NXP2+ showed a lower age at onset (p<0.0001) more frequent diagnosis of DM (68.8%vs30%,OR5.2) and IBM (6.5%vs0.49%,OR14.8), typical skin manifestations, myositis (93%vs79% OR3.3), concomitant presence of another MSA (12.7%vs2%, OR6.41) and lower rate of features associated with OM or anti-synthetase syndrome. Serum from 49 NXP2+ was available and IP analysis was made with the confirmation of NXP2 in 31 sera (63.2%) with the following diagnosis: DM 27 cases, PM 3, IBM 1. Whilst the majority of the associations were confirmed comparing NXP2LB+/IP+ with the IIM NXP2-, some peculiar associations were found significant only for the double positive patients: dysphagia (53%vs 30%,OR 2.56) and calcinosis (22%vs6.5% OR4) whereas IBM diagnosis and the presence of concomitant MSA antibodies were lost. Survival time from cancer onset is shown in figure.IP did not confirmed anti-NXP2 antibodies in 18 sera: in 4 cases at least one MSA/MAA was identified by IP; these 18 patients did not show differences when compared with 213 anti-NXP2-.Conclusion:Protein IP confirmed anti-NXP2 antibodies in 63% of LB+ sera. Double positive cases showed more typical DM features and rarely occurred in IIM not DM. Anti-NXP2 positivity by LB should be confirmed by other methods in order to correctly diagnose and characterize IIM patients.References:[1]Arthritis Res Ther 2012,30;14:R97Acknowledgments:Forum Italiano per la Ricerca Malattie Autoimmuni (FIRMA)Disclosure of Interests:Micaela Fredi: None declared, Ilaria Cavazzana: None declared, Angela Ceribelli: None declared, Maria Grazia Lazzaroni: None declared, Simone Barsotti: None declared, Maurizio Benucci: None declared, Lorenzo Cavagna: None declared, Ludovico De Stefano: None declared, Andrea Doria Consultant of: GSK, Pfizer, Abbvie, Novartis, Ely Lilly, Speakers bureau: UCB pharma, GSK, Pfizer, Janssen, Abbvie, Novartis, Ely Lilly, BMS, Giacomo Emmi: None declared, Marco Fornaro: None declared, Federica Furini: None declared, Roberto Gerli: None declared, Maria Grazia Giudizi: None declared, Marcello Govoni: None declared, Anna Ghirardello: None declared, Luca Iaccarino Speakers bureau: GSK, Pfizer, Janssen, Novartis, Florenzo Iannone Consultant of: Speaker and consulting fees from AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, MSD, Speakers bureau: Speaker and consulting fees from AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, MSD, Maria Infantino: None declared, Alessandro Mathieu: None declared, Emiliano Marasco: None declared, Paola Migliorini: None declared, Boaz Palterer: None declared, paola parronchi: None declared, Matteo Piga: None declared, Federico Pratesi: None declared, Antonella Radice: None declared, Carlo Selmi: None declared, Valeria Riccieri: None declared, Marilin Tampoia: None declared, Giovanni Zanframundo: None declared, Angela Tincani: None declared, Franco Franceschini: None declared
Collapse
|
17
|
Cai ZR, Lecours J, Adam JP, Marcil I, Blais N, Dallaire M, Belisle A, Mathieu A. Toxic epidermal necrolysis associated with pembrolizumab. J Oncol Pharm Pract 2019; 26:1259-1265. [PMID: 31810421 DOI: 10.1177/1078155219890659] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
INTRODUCTION Stevens-Johnson syndrome and toxic epidermal necrolysis are severe cutaneous drug eruptions characterized by epidermal detachment. Pembrolizumab is a monoclonal antibody that binds to the programmed death-1 receptor, and it has been associated with numerous cutaneous adverse side-effects, including Stevens-Johnson syndrome. CASE REPORT We describe a 63-year-old male with metastatic lung adenocarcinoma who developed a rapidly progressing maculopapular rash three days after a first dose of pembrolizumab. On day 16, the rash affected more than 80% of body surface area with detachment of large sheets of necrolytic epidermis in 30-40% of body surface area. However, the patient only presented with mild mucosal involvement. Histopathologic examination of a skin biopsy showed a subepidermal blister with overlying prominent full thickness epidermal keratinocytic necrosis and a superficial perivascular infiltrate of lymphocytes. A toxic epidermal necrolysis secondary to pembrolizumab was then diagnosed. Management and outcome: In addition to supportive cares, the patient received corticosteroids and cyclosporine. The patient responded rapidly to the immunosuppressant therapy, and nearly complete re-epithelialization was achieved 24 days after the start of the reaction. DISCUSSION In our review of the literature, 15 other cases of Stevens-Johnson syndrome/toxic epidermal necrolysis were reported with programmed death-1/programmed cell death ligand-1 inhibitors. To our knowledge, this is the first case of toxic epidermal necrolysis secondary to pembrolizumab published in the literature. The American Society of Clinical Oncology guidelines suggest that cyclosporine, in addition to corticosteroids, be initiated when toxic epidermal necrolysis is suspected. Clinicians should be aware of this rare dermatological emergency with the increasing use of pembrolizumab in oncology.
Collapse
Affiliation(s)
- Zhuo Ran Cai
- Department of Dermatology, Centre Hospitalier de l'Université de Montréal, Québec, Canada
| | - Julie Lecours
- Department of Dermatology, Centre Hospitalier de l'Université de Montréal, Québec, Canada
| | - Jean-Philippe Adam
- Department of Pharmacy, Centre Hospitalier de l'Université de Montréal, Québec, Canada.,Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada
| | - Isabelle Marcil
- Department of Dermatology, Centre Hospitalier de l'Université de Montréal, Québec, Canada
| | - Normand Blais
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada.,Department of Medicine, Service of Hematology, Oncology and Blood Bank, Centre Hospitalier de l'Université de Montréal, Québec, Canada
| | - Mario Dallaire
- Department of Medicine, Centre intégré de santé et des services sociaux de l'Outaouais, Québec, Canada
| | - Annie Belisle
- Department of Pathology, Centre Hospitalier de l'Université de Montréal, Québec, Canada
| | - Alexandre Mathieu
- Department of Pharmacy, Centre Hospitalier de l'Université de Montréal, Québec, Canada.,Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada
| |
Collapse
|
18
|
Florian RT, Kraft F, Leitão E, Kaya S, Klebe S, Magnin E, van Rootselaar AF, Buratti J, Kühnel T, Schröder C, Giesselmann S, Tschernoster N, Altmueller J, Lamiral A, Keren B, Nava C, Bouteiller D, Forlani S, Jornea L, Kubica R, Ye T, Plassard D, Jost B, Meyer V, Deleuze JF, Delpu Y, Avarello MDM, Vijfhuizen LS, Rudolf G, Hirsch E, Kroes T, Reif PS, Rosenow F, Ganos C, Vidailhet M, Thivard L, Mathieu A, Bourgeron T, Kurth I, Rafehi H, Steenpass L, Horsthemke B, LeGuern E, Klein KM, Labauge P, Bennett MF, Bahlo M, Gecz J, Corbett MA, Tijssen MAJ, van den Maagdenberg AMJM, Depienne C. Unstable TTTTA/TTTCA expansions in MARCH6 are associated with Familial Adult Myoclonic Epilepsy type 3. Nat Commun 2019; 10:4919. [PMID: 31664039 PMCID: PMC6820781 DOI: 10.1038/s41467-019-12763-9] [Citation(s) in RCA: 90] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Accepted: 09/23/2019] [Indexed: 12/30/2022] Open
Abstract
Familial Adult Myoclonic Epilepsy (FAME) is a genetically heterogeneous disorder characterized by cortical tremor and seizures. Intronic TTTTA/TTTCA repeat expansions in SAMD12 (FAME1) are the main cause of FAME in Asia. Using genome sequencing and repeat-primed PCR, we identify another site of this repeat expansion, in MARCH6 (FAME3) in four European families. Analysis of single DNA molecules with nanopore sequencing and molecular combing show that expansions range from 3.3 to 14 kb on average. However, we observe considerable variability in expansion length and structure, supporting the existence of multiple expansion configurations in blood cells and fibroblasts of the same individual. Moreover, the largest expansions are associated with micro-rearrangements occurring near the expansion in 20% of cells. This study provides further evidence that FAME is caused by intronic TTTTA/TTTCA expansions in distinct genes and reveals that expansions exhibit an unexpectedly high somatic instability that can ultimately result in genomic rearrangements.
Collapse
Affiliation(s)
- Rahel T Florian
- Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany
| | - Florian Kraft
- Institute of Human Genetics, Medical Faculty, RWTH Aachen University, 52062, Aachen, Germany
| | - Elsa Leitão
- Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany
| | - Sabine Kaya
- Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany
| | - Stephan Klebe
- Department of Neurology, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany
| | - Eloi Magnin
- Department of Neurology, CHU Jean Minjoz, 25000, Besançon, France
| | - Anne-Fleur van Rootselaar
- Departments of Neurology and Clinical Neurophysiology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands
| | - Julien Buratti
- AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique, 75013, Paris, France
| | - Theresa Kühnel
- Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany
| | - Christopher Schröder
- Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany
| | - Sebastian Giesselmann
- Institute of Human Genetics, Medical Faculty, RWTH Aachen University, 52062, Aachen, Germany
| | - Nikolai Tschernoster
- Cologne Center for Genomics, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Weyertal 115b, 50931, Cologne, Germany
| | - Janine Altmueller
- Cologne Center for Genomics, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Weyertal 115b, 50931, Cologne, Germany
| | - Anaide Lamiral
- Department of Neurology, CHU Jean Minjoz, 25000, Besançon, France
| | - Boris Keren
- AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique, 75013, Paris, France
| | - Caroline Nava
- AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique, 75013, Paris, France
- Institut du Cerveau et de la Moelle épinière (ICM), Sorbonne Université, UMR S 1127, Inserm U1127, CNRS UMR 7225, F-75013, Paris, France
| | - Delphine Bouteiller
- Institut du Cerveau et de la Moelle épinière (ICM), Sorbonne Université, UMR S 1127, Inserm U1127, CNRS UMR 7225, F-75013, Paris, France
| | - Sylvie Forlani
- Institut du Cerveau et de la Moelle épinière (ICM), Sorbonne Université, UMR S 1127, Inserm U1127, CNRS UMR 7225, F-75013, Paris, France
| | - Ludmila Jornea
- Institut du Cerveau et de la Moelle épinière (ICM), Sorbonne Université, UMR S 1127, Inserm U1127, CNRS UMR 7225, F-75013, Paris, France
| | - Regina Kubica
- Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany
| | - Tao Ye
- IGBMC, CNRS UMR 7104/INSERM U1258/Université de Strasbourg, 1 Rue Laurent Fries, 67400, Illkirch-Graffenstaden, France
| | - Damien Plassard
- IGBMC, CNRS UMR 7104/INSERM U1258/Université de Strasbourg, 1 Rue Laurent Fries, 67400, Illkirch-Graffenstaden, France
| | - Bernard Jost
- IGBMC, CNRS UMR 7104/INSERM U1258/Université de Strasbourg, 1 Rue Laurent Fries, 67400, Illkirch-Graffenstaden, France
| | - Vincent Meyer
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, F-91057, Evry, France
| | - Jean-François Deleuze
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, F-91057, Evry, France
| | - Yannick Delpu
- Genomic Vision, 80 Rue des Meuniers, 92220, Bagneux, France
| | | | - Lisanne S Vijfhuizen
- Department of Human Genetics, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands
| | - Gabrielle Rudolf
- IGBMC, CNRS UMR 7104/INSERM U1258/Université de Strasbourg, 1 Rue Laurent Fries, 67400, Illkirch-Graffenstaden, France
- Department of Neurology-centre de référence des epilepsies rares, University Hospital of Strasbourg, 1 Avenue Molière, 67200, Strasbourg, France
| | - Edouard Hirsch
- Department of Neurology-centre de référence des epilepsies rares, University Hospital of Strasbourg, 1 Avenue Molière, 67200, Strasbourg, France
| | - Thessa Kroes
- School of Biological Sciences, School of Medicine and Robinson Research Institute, The University of Adelaide, Adelaide, 5005, SA, Australia
| | - Philipp S Reif
- Epilepsy Center Frankfurt Rhine-Main, Department of Neurology, Goethe University and LOEWE Center for Personalized Translational Epilepsy Research (CePTER), 60323, Frankfurt am Main, Germany
- Department of Neurology, Epilepsy Center Hessen, Philipps University, 35037, Marburg, Germany
| | - Felix Rosenow
- Epilepsy Center Frankfurt Rhine-Main, Department of Neurology, Goethe University and LOEWE Center for Personalized Translational Epilepsy Research (CePTER), 60323, Frankfurt am Main, Germany
- Department of Neurology, Epilepsy Center Hessen, Philipps University, 35037, Marburg, Germany
| | - Christos Ganos
- Department of Neurology, Charité University Medicine Berlin, 10117, Berlin, Germany
| | - Marie Vidailhet
- Institut du Cerveau et de la Moelle épinière (ICM), Sorbonne Université, UMR S 1127, Inserm U1127, CNRS UMR 7225, F-75013, Paris, France
- APHP, Hôpital Pitié-Salpêtrière, Département de Neurologie, 75013, Paris, France
| | - Lionel Thivard
- APHP, Hôpital Pitié-Salpêtrière, Département de Neurologie, 75013, Paris, France
| | - Alexandre Mathieu
- Human Genetics and Cognitive Functions, Pasteur Institute, UMR3571 CNRS, Université de Paris, 75015, Paris, France
| | - Thomas Bourgeron
- Human Genetics and Cognitive Functions, Pasteur Institute, UMR3571 CNRS, Université de Paris, 75015, Paris, France
| | - Ingo Kurth
- Institute of Human Genetics, Medical Faculty, RWTH Aachen University, 52062, Aachen, Germany
| | - Haloom Rafehi
- Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, VIC, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, 3010, VIC, Australia
- Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, 3084, VIC, Australia
| | - Laura Steenpass
- Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany
| | - Bernhard Horsthemke
- Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany
| | - Eric LeGuern
- AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique, 75013, Paris, France
- Institut du Cerveau et de la Moelle épinière (ICM), Sorbonne Université, UMR S 1127, Inserm U1127, CNRS UMR 7225, F-75013, Paris, France
| | - Karl Martin Klein
- Epilepsy Center Frankfurt Rhine-Main, Department of Neurology, Goethe University and LOEWE Center for Personalized Translational Epilepsy Research (CePTER), 60323, Frankfurt am Main, Germany
- Department of Neurology, Epilepsy Center Hessen, Philipps University, 35037, Marburg, Germany
- Departments of Clinical Neurosciences, Medical Genetics and Community Health Sciences, Hotchkiss Brain Institute & Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, 2500 University Dr NW, Calgary, AB, T2N 1N4, Canada
| | - Pierre Labauge
- Department of Neurology, Gui de Chauliac University Hospital, 34295, Montpellier, France
| | - Mark F Bennett
- Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, VIC, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, 3010, VIC, Australia
- Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, 3084, VIC, Australia
| | - Melanie Bahlo
- Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, VIC, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, 3010, VIC, Australia
| | - Jozef Gecz
- School of Biological Sciences, School of Medicine and Robinson Research Institute, The University of Adelaide, Adelaide, 5005, SA, Australia
- South Australian Health and Medical Research Institute, The University of Adelaide, Adelaide, 5005, SA, Australia
| | - Mark A Corbett
- School of Biological Sciences, School of Medicine and Robinson Research Institute, The University of Adelaide, Adelaide, 5005, SA, Australia
| | - Marina A J Tijssen
- Department of Neurology, University Medical Center Groningen, University of Groningen, 9700, AB, Groningen, the Netherlands
| | - Arn M J M van den Maagdenberg
- Department of Human Genetics, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands
- Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Christel Depienne
- Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany.
- Institut du Cerveau et de la Moelle épinière (ICM), Sorbonne Université, UMR S 1127, Inserm U1127, CNRS UMR 7225, F-75013, Paris, France.
- IGBMC, CNRS UMR 7104/INSERM U1258/Université de Strasbourg, 1 Rue Laurent Fries, 67400, Illkirch-Graffenstaden, France.
| |
Collapse
|
19
|
Garrigues P, Su C, Reiss B, Mathieu A. Maladie cœliaque et adénocarcinome du duodénum : à propos d’une observation et revue de la littérature. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.03.274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Bortoluzzi A, Piga M, Silvagni E, Chessa E, Mathieu A, Govoni M. Peripheral nervous system involvement in systemic lupus erythematosus: a retrospective study on prevalence, associated factors and outcome. Lupus 2019; 28:465-474. [DOI: 10.1177/0961203319828499] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Background Despite its potentially significant impact on disease outcome, peripheral nervous system involvement in systemic lupus erythematosus has received little attention. Objective The objective of this study was to assess the prevalence and clinical features of peripheral nervous system involvement in a large cohort of systemic lupus erythematosus patients. Methods The records of systemic lupus erythematosus patients examined at two tertiary referral centres over a period of 14 years (from 2000 to 2014) were analyzed. Peripheral nervous system events were ascertained according to the 1999 American College of Rheumatology case definitions and by using an attribution algorithm for neuropsychiatric events. Prevalence of peripheral nervous system in systemic lupus erythematosus and demographic, clinical and laboratory features were assessed. Patients with peripheral nervous system events were compared with a control group of systemic lupus erythematosus patients without peripheral nervous system involvement. Results In a retrospective cohort of 1224 patients, the overall prevalence of peripheral nervous system involvement was 6.9% (85 patients, 95% confidence interval 0.06–0.08), with 68% of peripheral nervous system events attributable to systemic lupus erythematosus. Polyneuropathy was the most common manifestation observed (38 events, 39.2%), followed by cranial neuropathy in 30 cases (30.9%) and 12 cases of single (12.4%) or multiple (eight events, 8.2%) mononeuritis. The average age of systemic lupus erythematosus onset was significantly higher in patients with peripheral nervous system events than in controls (mean ± standard deviation: 45.9 ± 14.8 vs. 37.1 ± 14.0) and they were more likely to have higher SLEDAI-2K and SLICC/ACR Damage Index scores, as well as hypertension and livedo reticularis. A subgroup analysis of events deemed to be systemic lupus erythematosus-related provided similar results. Conclusion Peripheral nervous system manifestations are a potential complication of systemic lupus erythematosus. Careful neurological assessment should therefore be included in the diagnostic workup of patients with systemic lupus erythematosus, especially in those with later onset and greater damage and disease activity.
Collapse
Affiliation(s)
- A Bortoluzzi
- Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Cona (Ferrara), Italy
| | - M Piga
- Rheumatology Unit, University Clinic and AOU of Cagliari, Italy
| | - E Silvagni
- Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Cona (Ferrara), Italy
| | - E Chessa
- Rheumatology Unit, University Clinic and AOU of Cagliari, Italy
| | - A Mathieu
- Rheumatology Unit, University Clinic and AOU of Cagliari, Italy
| | - M Govoni
- Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Cona (Ferrara), Italy
| |
Collapse
|
21
|
El Raichani L, Du Q, Mathieu A, Almassy S, Lalonde L, Berbiche D, Gélinas‐Lemay E, Boudreau N, Cardinal H. Development and validation of PART (Pharmacotherapy Assessment in Renal Transplant Patients) criteria to assess drug-related problems in an outpatient renal transplant population: A cross-sectional study. Pharmacol Res Perspect 2019; 7:e00453. [PMID: 30675363 PMCID: PMC6333916 DOI: 10.1002/prp2.453] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Accepted: 12/03/2018] [Indexed: 11/09/2022] Open
Abstract
Kidney transplant recipients are at risk of pharmacological interactions and adverse drug reactions. Community pharmacists are uniquely poised to detect and intervene in cases of drug-related problems. The aims of this study were to develop and validate a list of explicit criteria to be used by community pharmacists to assess drug-related problems in kidney transplant patients, and to assess their frequency and their determinants. First, we used a modified RAND method where a panel of experts established the PART (Pharmacotherapy Assessment in Renal Transplant Patient) criteria. Then, we performed a cross-sectional study in which we applied the PART criteria to 97 prevalent kidney transplant recipients followed at a single university-affiliated center. The final list of PART criteria included 70 drug-related problems and was reliable (kappa: 0.88). An average of 1.2 drug-related problems per patient was detected when the PART criteria were applied, with 68% of patients having at least 1 problem. This figure was 1.4 per patient using the expert judgment of renal transplant pharmacists who had no access to the PART list. The total number of medications taken was the only factor associated with the number of drug-related problems (β: 0.27 for an increase of five medications, 95% CI 0.005, 0.547). The PART criteria provide a novel tool for community pharmacists to systematically detect drug-related problems in kidney transplant recipients.
Collapse
Affiliation(s)
- Layal El Raichani
- Department of PharmacyCentre intégré de santé et de services sociaux CISSS de la Montérégie CentreLongueuilQuebecCanada
- Faculty of PharmacyUniversity of MontrealMontrealQuebecCanada
| | - Qian Du
- Faculty of PharmacyUniversity of MontrealMontrealQuebecCanada
- Department of PharmacyCentre intégré universitaire de santé et de services sociaux du Centre‐Sud‐de‐l’île‐MontréalMontrealQuebecCanada
| | - Alexandre Mathieu
- Faculty of PharmacyUniversity of MontrealMontrealQuebecCanada
- Department of PharmacyCentre Hospitalier de l'Université de MontréalMontrealQuebecCanada
| | - Sabrina Almassy
- Faculty of PharmacyUniversity of MontrealMontrealQuebecCanada
- Department of PharmacyCentre intégré universitaire de santé et de services sociaux de l'EstrieSherbrookeQuebecCanada
| | - Lyne Lalonde
- Faculty of PharmacyUniversity of MontrealMontrealQuebecCanada
| | - Djamal Berbiche
- Faculty of Medicine and Health SciencesUniversité de SherbrookeSherbrookeQuebecCanada
| | - Elisabeth Gélinas‐Lemay
- Faculty of PharmacyUniversity of MontrealMontrealQuebecCanada
- Department of PharmacyCentre Hospitalier de l'Université de MontréalMontrealQuebecCanada
| | - Nathalie Boudreau
- Faculty of PharmacyUniversity of MontrealMontrealQuebecCanada
- Department of PharmacyCentre Hospitalier de l'Université de MontréalMontrealQuebecCanada
- Research centerCentre Hospitalier de l'Université de MontréalMontrealQuebecCanada
| | - Héloïse Cardinal
- Research centerCentre Hospitalier de l'Université de MontréalMontrealQuebecCanada
- Nephrology DivisionCentre Hospitalier de l'Université de MontréalMontrealQuebecCanada
| |
Collapse
|
22
|
Bouvet L, Amsellem F, Maruani A, Tonus-Vic Dupont A, Mathieu A, Bourgeron T, Delorme R, Mottron L. Synesthesia & autistic features in a large family: Evidence for spatial imagery as a common factor. Behav Brain Res 2019; 362:266-272. [PMID: 30639511 DOI: 10.1016/j.bbr.2019.01.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Revised: 01/08/2019] [Accepted: 01/08/2019] [Indexed: 12/24/2022]
Abstract
BACKGROUND Autism and synesthesia are neurodevelopmental conditions associated with variants of perceptual processing. They also share some genetic variants and include a large magnitude of intra-categorical variation: 60 types for synesthesia, as well as a spectrum for autism. In order to investigate the relationship between these two phenomena, we investigated the family of FC, an autistic individual who also possess savant abilities and synesthesia manifestations. METHOD Autistic symptoms were assessed for the entire sample of participants entering the study (39 individuals) using the SRS. Participants above threshold were evaluated with standardized diagnostic tools. Synesthesia was explored in the entire participating sample using a self-reported questionnaire. Consistency tests were used for participants who reported synesthetic manifestations. RESULTS In addition to FC, four individuals with ASD were detected. Fifteen participants self-reported synesthesia (15 sequence-space, 4 sound-shape, 4 day-color), among which nine sequence-space synesthetes satisfied the consistency criteria. Two participants possess both autism and synesthesia. CONCLUSION This family illustrates the co-segregation of autism and synesthesia. This co-segregation is in favour of a partially overlapping genetic predisposition for both conditions, but also authorizes a large variety of manifestations in both conditions. The high prevalence of sequence-space synesthesia in this family strengthens the previous assumption that this form of synesthesia may be linked to autism. We discuss the potential role of spatial imagery in the development of this form of synesthesia and savant abilities.
Collapse
Affiliation(s)
- Lucie Bouvet
- Laboratoire CERPPS (EA7411), Université Toulouse Jean Jaurés, Toulouse, France.
| | - Frédérique Amsellem
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France; Child and Adolescent Psychiatry Department, Hôpital Robert-Debré, APHP, 75019, Paris, France; Fondation FondaMental, 94000, Créteil, France
| | - Anna Maruani
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France; Child and Adolescent Psychiatry Department, Hôpital Robert-Debré, APHP, 75019, Paris, France
| | - Adelaïde Tonus-Vic Dupont
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France; Child and Adolescent Psychiatry Department, Hôpital Robert-Debré, APHP, 75019, Paris, France
| | - Alexandre Mathieu
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France; CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
| | - Thomas Bourgeron
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France; CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France; Fondation FondaMental, 94000, Créteil, France; Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - Richard Delorme
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France; CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France; Child and Adolescent Psychiatry Department, Hôpital Robert-Debré, APHP, 75019, Paris, France; Fondation FondaMental, 94000, Créteil, France; Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - Laurent Mottron
- Center of Excellence for Pervasive Developmental Disorders of the University of Montreal (CETEDUM), Rivières-des-Prairies Hospital, Montreal, Quebec, Canada; Research Center of CIUSSS of the North of Montreal and Department of Psychiatry, University of Montreal, Montreal, Quebec, Canada
| |
Collapse
|
23
|
Lahbib S, Leblond CS, Hamza M, Regnault B, Lemée L, Mathieu A, Jaouadi H, Mkaouar R, Youssef-Turki IB, Belhadj A, Kraoua I, Bourgeron T, Abdelhak S. Homozygous 2p11.2 deletion supports the implication of ELMOD3 in hearing loss and reveals the potential association of CAPG with ASD/ID etiology. J Appl Genet 2018; 60:49-56. [PMID: 30284680 DOI: 10.1007/s13353-018-0472-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2018] [Revised: 09/25/2018] [Accepted: 09/27/2018] [Indexed: 11/30/2022]
Abstract
Autism spectrum disorder (ASD) is a set of neurodevelopmental conditions characterized by early-onset difficulties in social communication and unusually restricted, repetitive behavior and interests. Parental consanguinity may lead to higher risk of ASD and to more severe clinical presentations in the offspring. Studies of ASD families with high inbreeding enable the identification of inherited variants of this disorder particularly those with an autosomal recessive pattern of inheritance. In our study, using copy number variants (CNV) analysis, we identified a rare homozygous deletion in 2p11.2 region that affects ELMOD3, CAPG, and SH2D6 genes in a boy with ASD, intellectual disability (ID), and hearing impairment (HI). This deletion may reveal a new contiguous deletion syndrome in which ELMOD3, known to be implicated in autosomal recessive deafness underlies the HI of the proband and CAPG, member of actin regulatory proteins involved in cytoskeletal dynamic, an important function for brain development and activity, underlies the ASD/ID phenotype. A possible contribution of SH2D6 gene, as a part of a chimeric gene, to the clinical presentation of the patient is discussed. Our result supports the implication of ELMOD3 in hearing loss and highlights the potential clinical relevance of 2p11.2 deletion in autism and/or intellectual disability.
Collapse
Affiliation(s)
- Saida Lahbib
- Biomedical Genomics and Oncogenetics Laboratory LR16IPT05, Université Tunis El Manar, Institut Pasteur de Tunis, 1002, Tunis, Tunisia. .,University of Tunis El Manar, Tunis, Tunisia.
| | - Claire S Leblond
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, 75015, Paris, France.,CNRS UMR3571, Genes, Synapses and Cognition, Institut Pasteur, 75015, Paris, France.,Paris Diderot University, Sorbonne Paris Cité, 75013, Paris, France
| | - Mariem Hamza
- Faculty of Medicine of Tunis, University of Tunis El Manar, 1007 La Rabta, Tunis, Tunisia.,Child and Adolescent Psychiatry Department, Mongi Slim Hospital, 2046, Sidi Daoud, Tunisia
| | - Béatrice Regnault
- Plateforme de Génotypage des Eucaryotes, Centre d'Innovation et Recherche Technologique (CITECH), Institut Pasteur, 75015, Paris, France
| | - Laure Lemée
- Plateforme de Génotypage des Eucaryotes, Centre d'Innovation et Recherche Technologique (CITECH), Institut Pasteur, 75015, Paris, France
| | - Alexandre Mathieu
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, 75015, Paris, France.,CNRS UMR3571, Genes, Synapses and Cognition, Institut Pasteur, 75015, Paris, France.,Paris Diderot University, Sorbonne Paris Cité, 75013, Paris, France
| | - Hager Jaouadi
- Biomedical Genomics and Oncogenetics Laboratory LR16IPT05, Université Tunis El Manar, Institut Pasteur de Tunis, 1002, Tunis, Tunisia
| | - Rahma Mkaouar
- Biomedical Genomics and Oncogenetics Laboratory LR16IPT05, Université Tunis El Manar, Institut Pasteur de Tunis, 1002, Tunis, Tunisia
| | - Ilhem Ben Youssef-Turki
- Faculty of Medicine of Tunis, University of Tunis El Manar, 1007 La Rabta, Tunis, Tunisia.,Research Unit UR12 SP24 and Department of Child and Adolescent Neurology, National Institute Mongi Ben Hmida of Neurology, 1007, Tunis, Tunisia
| | - Ahlem Belhadj
- Faculty of Medicine of Tunis, University of Tunis El Manar, 1007 La Rabta, Tunis, Tunisia.,Child and Adolescent Psychiatry Department, Mongi Slim Hospital, 2046, Sidi Daoud, Tunisia
| | - Ichraf Kraoua
- Faculty of Medicine of Tunis, University of Tunis El Manar, 1007 La Rabta, Tunis, Tunisia.,Research Unit UR12 SP24 and Department of Child and Adolescent Neurology, National Institute Mongi Ben Hmida of Neurology, 1007, Tunis, Tunisia
| | - Thomas Bourgeron
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, 75015, Paris, France.,CNRS UMR3571, Genes, Synapses and Cognition, Institut Pasteur, 75015, Paris, France.,Paris Diderot University, Sorbonne Paris Cité, 75013, Paris, France
| | - Sonia Abdelhak
- Biomedical Genomics and Oncogenetics Laboratory LR16IPT05, Université Tunis El Manar, Institut Pasteur de Tunis, 1002, Tunis, Tunisia
| |
Collapse
|
24
|
Nicolay N, Boulet L, Le Bourhis-Zaimi M, Henry L, Erouart S, Mathieu A, Borgey F. Factors associated with a prolonged Norovirus outbreak in a nursing home, Normandy, France, 2016. Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.05.496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
25
|
Sebastiani GD, Prevete I, Iuliano A, Piga M, Iannone F, Coladonato L, Govoni M, Bortoluzzi A, Mosca M, Tani C, Doria A, Iaccarino L, Tincani A, Fredi M, Conti F, Spinelli FR, Galeazzi M, Bellisai F, Zanetti A, Carrara G, Scirè CA, Mathieu A. Early Lupus Project: one-year follow-up of an Italian cohort of patients with systemic lupus erythematosus of recent onset. Lupus 2018; 27:1479-1488. [DOI: 10.1177/0961203318777112] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Objective To describe the clinical and serological features of a prospectively followed cohort of early diagnosed systemic lupus erythematosus (SLE) patients during a one-year follow-up period. Methods SLE patients with disease duration less than 12 months were consecutively enrolled in a multicentre, prospective study. At study entry and then every 6 months, a large panel of data was recorded. Results Of 260 patients enrolled, 185 had at least 12 months of follow-up; of these, 84.3% were female, 92.4% were Caucasians. Mean diagnostic delay was about 20 months; higher values of European Consensus Lupus Activity Measurement (ECLAM) and of organs/systems involved were both associated with shorter diagnostic delay. Clinical and serological parameters improved after study entry. However, patients' quality of life deteriorated and cardiovascular risk factors significantly increased. About one-third of patients with active disease at study entry went into remission (ECLAM = 0). Negative predictors for remission were: oral ulcers, arthritis, low C4, anti-SSB (Ro) antibodies and therapy with mycophenolate. There was a widespread use of glucocorticoids both at baseline and during follow-up. Conclusion Clinical symptoms and serological parameters improve during the first period after diagnosis. However, patients’ quality of life deteriorates. The widespread use of glucocorticoids is probably the reason for the early significant increase of some cardiovascular risk factors.
Collapse
Affiliation(s)
- G D Sebastiani
- UOC Reumatologia, Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy
| | - I Prevete
- UOC Reumatologia, Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy
| | - A Iuliano
- UOC Reumatologia, Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy
| | - M Piga
- Cattedra e Struttura Complessa di Reumatologia, Università degli Studi e AOU di Cagliari, Italy
| | - F Iannone
- Dipartimento Interdisciplinare di Medicina - Sezione di Reumatologia, Universita' di Bari, Italy
| | - L Coladonato
- Dipartimento Interdisciplinare di Medicina - Sezione di Reumatologia, Universita' di Bari, Italy
| | - M Govoni
- UO e Sezione di Reumatologia - Dipartimento di Scienze Mediche, Università degli Studi di Ferrara, Italy
| | - A Bortoluzzi
- UO e Sezione di Reumatologia - Dipartimento di Scienze Mediche, Università degli Studi di Ferrara, Italy
| | - M Mosca
- UO Reumatologia, Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Italy
| | - C Tani
- UO Reumatologia, Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Italy
| | - A Doria
- Rheumatology Unit, Department of Medicine, University of Padova, Italy
| | - L Iaccarino
- Rheumatology Unit, Department of Medicine, University of Padova, Italy
| | - A Tincani
- UOC Reumatologia e Immunologia Clinica, Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, ASST Spedali Civili – Brescia, Italy
| | - M Fredi
- UOC Reumatologia e Immunologia Clinica, Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, ASST Spedali Civili – Brescia, Italy
| | - F Conti
- Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Italy
| | - F R Spinelli
- Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Italy
| | - M Galeazzi
- UOC di Reumatologia, Azienda Ospedaliera Universitaria Senese, Italy
| | - F Bellisai
- UOC di Reumatologia, Azienda Ospedaliera Universitaria Senese, Italy
| | - A Zanetti
- Centro Studi SIR (Società Italiana di Reumatologia), Italy
| | - G Carrara
- Centro Studi SIR (Società Italiana di Reumatologia), Italy
| | - C A Scirè
- Centro Studi SIR (Società Italiana di Reumatologia), Italy
| | - A Mathieu
- Cattedra e Struttura Complessa di Reumatologia, Università degli Studi e AOU di Cagliari, Italy
| |
Collapse
|
26
|
Huguet G, Schramm C, Douard E, Jiang L, Labbe A, Tihy F, Mathonnet G, Nizard S, Lemyre E, Mathieu A, Poline JB, Loth E, Toro R, Schumann G, Conrod P, Pausova Z, Greenwood C, Paus T, Bourgeron T, Jacquemont S. Measuring and Estimating the Effect Sizes of Copy Number Variants on General Intelligence in Community-Based Samples. JAMA Psychiatry 2018; 75:447-457. [PMID: 29562078 PMCID: PMC5875373 DOI: 10.1001/jamapsychiatry.2018.0039] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
IMPORTANCE; Copy number variants (CNVs) classified as pathogenic are identified in 10% to 15% of patients referred for neurodevelopmental disorders. However, their effect sizes on cognitive traits measured as a continuum remain mostly unknown because most of them are too rare to be studied individually using association studies. OBJECTIVE To measure and estimate the effect sizes of recurrent and nonrecurrent CNVs on IQ. DESIGN, SETTING, AND PARTICIPANTS This study identified all CNVs that were 50 kilobases (kb) or larger in 2 general population cohorts (the IMAGEN project and the Saguenay Youth Study) with measures of IQ. Linear regressions, including functional annotations of genes included in CNVs, were used to identify features to explain their association with IQ. Validation was performed using intraclass correlation that compared IQ estimated by the model with empirical data. MAIN OUTCOMES AND MEASURES Performance IQ (PIQ), verbal IQ (VIQ), and frequency of de novo CNV events. RESULTS The study included 2090 European adolescents from the IMAGEN study and 1983 children and parents from the Saguenay Youth Study. Of these, genotyping was performed on 1804 individuals from IMAGEN and 977 adolescents, 445 mothers, and 448 fathers (484 families) from the Saguenay Youth Study. We observed 4928 autosomal CNVs larger than 50 kb across both cohorts. For rare deletions, size, number of genes, and exons affect IQ, and each deleted gene is associated with a mean (SE) decrease in PIQ of 0.67 (0.19) points (P = 6 × 10-4); this is not so for rare duplications and frequent CNVs. Among 10 functional annotations, haploinsufficiency scores best explain the association of any deletions with PIQ with a mean (SE) decrease of 2.74 (0.68) points per unit of the probability of being loss-of-function intolerant (P = 8 × 10-5). Results are consistent across cohorts and unaffected by sensitivity analyses removing pathogenic CNVs. There is a 0.75 concordance (95% CI, 0.39-0.91) between the effect size on IQ estimated by our model and IQ loss calculated in previous studies of 15 recurrent CNVs. There is a close association between effect size on IQ and the frequency at which deletions occur de novo (odds ratio, 0.86; 95% CI, 0.84-0.87; P = 2.7 × 10-88). There is a 0.76 concordance (95% CI, 0.41-0.91) between de novo frequency estimated by the model and calculated using data from the DECIPHER database. CONCLUSIONS AND RELEVANCE Models trained on nonpathogenic deletions in the general population reliably estimate the effect size of pathogenic deletions and suggest omnigenic associations of haploinsufficiency with IQ. This represents a new framework to study variants too rare to perform individual association studies and can help estimate the cognitive effect of undocumented deletions in the neurodevelopmental clinic.
Collapse
Affiliation(s)
- Guillaume Huguet
- Department of Pediatrics, Université de Montréal, Montreal, Quebec, Canada,Center Hospitalier Universitaire Sainte-Justine Research Center, Montreal, Quebec, Canada
| | - Catherine Schramm
- Department of Pediatrics, Université de Montréal, Montreal, Quebec, Canada,Center Hospitalier Universitaire Sainte-Justine Research Center, Montreal, Quebec, Canada,Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
| | - Elise Douard
- Department of Pediatrics, Université de Montréal, Montreal, Quebec, Canada,Center Hospitalier Universitaire Sainte-Justine Research Center, Montreal, Quebec, Canada
| | - Lai Jiang
- Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
| | - Aurélie Labbe
- Département de Sciences de la Décision, HEC Montreal, Montreal, Quebec, Canada
| | - Frédérique Tihy
- Department of Pediatrics, Université de Montréal, Montreal, Quebec, Canada,Center Hospitalier Universitaire Sainte-Justine Research Center, Montreal, Quebec, Canada
| | - Géraldine Mathonnet
- Department of Pediatrics, Université de Montréal, Montreal, Quebec, Canada,Center Hospitalier Universitaire Sainte-Justine Research Center, Montreal, Quebec, Canada
| | - Sonia Nizard
- Department of Pediatrics, Université de Montréal, Montreal, Quebec, Canada,Center Hospitalier Universitaire Sainte-Justine Research Center, Montreal, Quebec, Canada
| | - Emmanuelle Lemyre
- Department of Pediatrics, Université de Montréal, Montreal, Quebec, Canada,Center Hospitalier Universitaire Sainte-Justine Research Center, Montreal, Quebec, Canada
| | - Alexandre Mathieu
- Department of Neurosciences, Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France,Centre National de la Recherche Scientifique Genes, Synapses and Cognition Laboratory, Institut Pasteur, Paris, France
| | | | - Eva Loth
- Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, England
| | - Roberto Toro
- Department of Neurosciences, Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France,Centre National de la Recherche Scientifique Genes, Synapses and Cognition Laboratory, Institut Pasteur, Paris, France
| | - Gunter Schumann
- Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, England
| | - Patricia Conrod
- Department of Pediatrics, Université de Montréal, Montreal, Quebec, Canada,Center Hospitalier Universitaire Sainte-Justine Research Center, Montreal, Quebec, Canada,Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, England
| | - Zdenka Pausova
- The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
| | - Celia Greenwood
- Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada,Departments of Human Genetics and Oncology, McGill University, Montreal, Quebec, Canada
| | - Tomas Paus
- Rotman Research Institute, Baycrest, Toronto, Ontario, Canada,Departments of Psychology and Psychiatry, University of Toronto, Toronto, Ontario, Canada,Child Mind Institute, New York, New York
| | - Thomas Bourgeron
- Department of Neurosciences, Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France,Centre National de la Recherche Scientifique Genes, Synapses and Cognition Laboratory, Institut Pasteur, Paris, France,Human Genetics and Cognitive Functions, University Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Sébastien Jacquemont
- Department of Pediatrics, Université de Montréal, Montreal, Quebec, Canada,Center Hospitalier Universitaire Sainte-Justine Research Center, Montreal, Quebec, Canada
| | | |
Collapse
|
27
|
Chauvin A, Mathieu A, Lacasse V, Wang C, Geha S, Garde-Granger P, Boisvert F. A256 DETERMINATION OF PROTEOMIC SIGNATURE OF RESPONSE TO NEOADJUVANT RADIO-CHEMOTHERAPY IN COLORECTAL CANCER PATIENTS. J Can Assoc Gastroenterol 2018. [DOI: 10.1093/jcag/gwy008.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- A Chauvin
- Université de Sherbrooke, Sherbrooke, QC, Canada
| | - A Mathieu
- Université de Sherbrooke, Sherbrooke, QC, Canada
| | - V Lacasse
- Université de Sherbrooke, Sherbrooke, QC, Canada
| | - C Wang
- Université de Sherbrooke, Sherbrooke, QC, Canada
| | - S Geha
- Université de Sherbrooke, Sherbrooke, QC, Canada
| | | | - F Boisvert
- Anatomy and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada
| |
Collapse
|
28
|
Chessa E, Piga M, Floris A, Mathieu A, Cauli A. Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series. Reumatismo 2017; 69:175-183. [DOI: 10.4081/reumatismo.2017.1007] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Revised: 07/19/2017] [Accepted: 08/04/2017] [Indexed: 11/22/2022] Open
Abstract
Demyelinating syndrome (DS) is a rare manifestation of systemic lupus erythematosus (SLE) (1%) with high clinical heterogeneity and potentially severe prognosis. It can represent a diagnostic and therapeutic challenge for clinicians. A recent study described 5 different patterns of demyelinating disease presentation, characterised by specific clinical, laboratory and brain and spine magnetic resonance imaging abnormalities: 1) neuromyelitis optica; 2) neuromyelitis optica spectrum disorders; 3) DS prevalently involving the brain; 4) DS prevalently involving the brainstem; 5) clinically isolated syndrome. In this review we briefly discuss typical characteristics of each DS presentation in SLE and we describe 5 illustrative clinical cases, one for each subset of DS, considering both diagnostic and therapeutic options.
Collapse
|
29
|
Tabet AC, Rolland T, Ducloy M, Lévy J, Buratti J, Mathieu A, Haye D, Perrin L, Dupont C, Passemard S, Capri Y, Verloes A, Drunat S, Keren B, Mignot C, Marey I, Jacquette A, Whalen S, Pipiras E, Benzacken B, Chantot-Bastaraud S, Afenjar A, Héron D, Le Caignec C, Beneteau C, Pichon O, Isidor B, David A, El Khattabi L, Kemeny S, Gouas L, Vago P, Mosca-Boidron AL, Faivre L, Missirian C, Philip N, Sanlaville D, Edery P, Satre V, Coutton C, Devillard F, Dieterich K, Vuillaume ML, Rooryck C, Lacombe D, Pinson L, Gatinois V, Puechberty J, Chiesa J, Lespinasse J, Dubourg C, Quelin C, Fradin M, Journel H, Toutain A, Martin D, Benmansour A, Leblond CS, Toro R, Amsellem F, Delorme R, Bourgeron T. A framework to identify contributing genes in patients with Phelan-McDermid syndrome. NPJ Genom Med 2017; 2:32. [PMID: 29263841 PMCID: PMC5677962 DOI: 10.1038/s41525-017-0035-2] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2017] [Revised: 06/23/2017] [Accepted: 09/26/2017] [Indexed: 01/08/2023] Open
Abstract
Phelan-McDermid syndrome (PMS) is characterized by a variety of clinical symptoms with heterogeneous degrees of severity, including intellectual disability (ID), absent or delayed speech, and autism spectrum disorders (ASD). It results from a deletion of the distal part of chromosome 22q13 that in most cases includes the SHANK3 gene. SHANK3 is considered a major gene for PMS, but the factors that modulate the severity of the syndrome remain largely unknown. In this study, we investigated 85 patients with different 22q13 rearrangements (78 deletions and 7 duplications). We first explored the clinical features associated with PMS, and provide evidence for frequent corpus callosum abnormalities in 28% of 35 patients with brain imaging data. We then mapped several candidate genomic regions at the 22q13 region associated with high risk of clinical features, and suggest a second locus at 22q13 associated with absence of speech. Finally, in some cases, we identified additional clinically relevant copy-number variants (CNVs) at loci associated with ASD, such as 16p11.2 and 15q11q13, which could modulate the severity of the syndrome. We also report an inherited SHANK3 deletion transmitted to five affected daughters by a mother without ID nor ASD, suggesting that some individuals could compensate for such mutations. In summary, we shed light on the genotype-phenotype relationship of patients with PMS, a step towards the identification of compensatory mechanisms for a better prognosis and possibly treatments of patients with neurodevelopmental disorders.
Collapse
Affiliation(s)
- Anne-Claude Tabet
- Genetics Department, Robert Debré Hospital, APHP, Paris, France
- Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France
- CNRS UMR 3571 Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Université Paris Diderot, Paris, France
| | - Thomas Rolland
- Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France
- CNRS UMR 3571 Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Université Paris Diderot, Paris, France
| | - Marie Ducloy
- Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France
- CNRS UMR 3571 Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Université Paris Diderot, Paris, France
| | - Jonathan Lévy
- Genetics Department, Robert Debré Hospital, APHP, Paris, France
| | - Julien Buratti
- Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France
- CNRS UMR 3571 Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Université Paris Diderot, Paris, France
| | - Alexandre Mathieu
- Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France
- CNRS UMR 3571 Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Université Paris Diderot, Paris, France
| | - Damien Haye
- Genetics Department, Robert Debré Hospital, APHP, Paris, France
| | - Laurence Perrin
- Genetics Department, Robert Debré Hospital, APHP, Paris, France
| | - Céline Dupont
- Genetics Department, Robert Debré Hospital, APHP, Paris, France
| | | | - Yline Capri
- Genetics Department, Robert Debré Hospital, APHP, Paris, France
| | - Alain Verloes
- Genetics Department, Robert Debré Hospital, APHP, Paris, France
| | - Séverine Drunat
- Genetics Department, Robert Debré Hospital, APHP, Paris, France
| | - Boris Keren
- Cytogenetics Unit, Pitié Salpetrière Hospital, APHP, Paris, France
| | - Cyril Mignot
- Neurogenetics Unit, Pitié Salpetrière Hospital, APHP, Paris, France
| | - Isabelle Marey
- Clinical Genetics Unit, Pitié Salpetrière Hospital, APHP, Paris, France
| | - Aurélia Jacquette
- Clinical Genetics Unit, Pitié Salpetrière Hospital, APHP, Paris, France
| | - Sandra Whalen
- Clinical Genetics Unit, Pitié Salpetrière Hospital, APHP, Paris, France
| | - Eva Pipiras
- Cytogenetics Unit, Jean Verdier Hospital, APHP, Bondy, France
| | | | | | | | - Delphine Héron
- Clinical Genetics Unit, Trousseau Hospital, APHP, Paris, France
| | | | | | | | | | - Albert David
- Clinical Genetics Unit, Nantes Hospital, Nantes, France
| | | | | | | | - Philippe Vago
- Genetics Unit, CHU Estaing, Clermont-Ferrand, France
| | | | | | | | - Nicole Philip
- Genetics Unit, La Timone Hospital, Marseille, France
| | | | - Patrick Edery
- Clinical Genetics Unit, Lyon Civil Hospital, Lyon, France
| | | | | | | | | | | | | | | | - Lucile Pinson
- Genetics Unit, Montpellier Hospital, Montpellier, France
| | | | | | | | - James Lespinasse
- Cytogenetics Unit, Chambéry-Hôtel-Dieu Hospital, Chambéry, France
| | | | | | | | | | | | | | | | - Claire S. Leblond
- Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France
- CNRS UMR 3571 Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Université Paris Diderot, Paris, France
| | - Roberto Toro
- Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France
- CNRS UMR 3571 Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Université Paris Diderot, Paris, France
| | - Frédérique Amsellem
- Department of Child and Adolescent Psychiatry, Robert Debré Hospital, APHP, Paris, France
| | - Richard Delorme
- Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France
- CNRS UMR 3571 Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Université Paris Diderot, Paris, France
- Department of Child and Adolescent Psychiatry, Robert Debré Hospital, APHP, Paris, France
| | - Thomas Bourgeron
- Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France
- CNRS UMR 3571 Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Université Paris Diderot, Paris, France
| |
Collapse
|
30
|
Albert A, André M, Anghinolfi M, Anton G, Ardid M, Aubert JJ, Avgitas T, Baret B, Barrios-Martí J, Basa S, Bertin V, Biagi S, Bormuth R, Bourret S, Bouwhuis M, Bruijn R, Brunner J, Busto J, Capone A, Caramete L, Carr J, Celli S, Chiarusi T, Circella M, Coelho J, Coleiro A, Coniglione R, Costantini H, Coyle P, Creusot A, Deschamps A, De Bonis G, Distefano C, Di Palma I, Donzaud C, Dornic D, Drouhin D, Eberl T, El Bojaddaini I, Elsässer D, Enzenhöfer A, Felis I, Fusco L, Galatà S, Gay P, Giordano V, Glotin H, Grégoire T, Gracia Ruiz R, Graf K, Hallmann S, van Haren H, Heijboer A, Hello Y, Hernández-Rey J, Hößl J, Hofestädt J, Hugon C, Illuminati G, James C, de Jong M, Jongen M, Kadler M, Kalekin O, Katz U, Kießling D, Kouchner A, Kreter M, Kreykenbohm I, Kulikovskiy V, Lachaud C, Lahmann R, Lefèvre D, Leonora E, Lotze M, Loucatos S, Marcelin M, Margiotta A, Marinelli A, Martínez-Mora J, Mathieu A, Mele R, Melis K, Michael T, Migliozzi P, Moussa A, Nezri E, Păvălaş G, Pellegrino C, Perrina C, Piattelli P, Popa V, Pradier T, Quinn L, Racca C, Riccobene G, Sánchez-Losa A, Saldaña M, Salvadori I, Samtleben D, McIver J, McManus D, McRae T, McWilliams S, Meacher D, Meadors G, Meidam J, Melatos A, Mendell G, Mendoza-Gandara D, Sanguineti M, Mercer R, Merilh E, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers P, Mezzani F, Miao H, Sapienza P, Michel C, Middleton H, Mikhailov E, Milano L, Miller A, Miller A, Miller B, Miller J, Millhouse M, Minenkov Y, Schüssler F, Ming J, Mirshekari S, Mishra C, Mitra S, Mitrofanov V, Mitselmakher G, Mittleman R, Moggi A, Mohan M, Mohapatra S, Sieger C, Montani M, Moore B, Moore C, Moraru D, Moreno G, Morriss S, Mours B, Mow-Lowry C, Mueller G, Muir A, Spurio M, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muniz E, Murray P, Mytidis A, Napier K, Stolarczyk T, Nardecchia I, Naticchioni L, Nelemans G, Nelson T, Neri M, Nery M, Neunzert A, Newport J, Newton G, Nguyen T, Taiuti M, Nielsen A, Nissanke S, Nitz A, Noack A, Nocera F, Nolting D, Normandin M, Nuttall L, Oberling J, Ochsner E, Tayalati Y, Oelker E, Ogin G, Oh J, Oh S, Ohme F, Oliver M, Oppermann P, Oram RJ, O’Reilly B, O’Shaughnessy R, Trovato A, Ottaway D, Overmier H, Owen B, Pace A, Page J, Pai A, Pai S, Palamos J, Palashov O, Palomba C, Turpin D, Pal-Singh A, Pan H, Pankow C, Pannarale F, Pant B, Paoletti F, Paoli A, Papa M, Paris H, Parker W, Tönnis C, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patricelli B, Pearlstone B, Pedraza M, Pedurand R, Pekowsky L, Pele A, Vallage B, Penn S, Perez C, Perreca A, Perri L, Pfeiffer H, Phelps M, Piccinni O, Pichot M, Piergiovanni F, Pierro V, Vallée C, Pillant G, Pinard L, Pinto I, Pitkin M, Poe M, Poggiani R, Popolizio P, Post A, Powell J, Prasad J, Van Elewyck V, Pratt J, Predoi V, Prestegard T, Prijatelj M, Principe M, Privitera S, Prodi G, Prokhorov L, Puncken O, Punturo M, Versari F, Puppo P, Pürrer M, Qi H, Qin J, Qiu S, Quetschke V, Quintero E, Quitzow-James R, Raab F, Rabeling D, Vivolo D, Radkins H, Raffai P, Raja S, Rajan C, Rakhmanov M, Rapagnani P, Raymond V, Razzano M, Re V, Read J, Vizzoca A, Regimbau T, Rei L, Reid S, Reitze D, Rew H, Reyes S, Rhoades E, Ricci F, Riles K, Rizzo M, Wilms J, Robertson N, Robie R, Robinet F, Rocchi A, Rolland L, Rollins J, Roma V, Romano R, Romie J, Rosińska D, Zornoza J, Rowan S, Rüdiger A, Ruggi P, Ryan K, Sachdev S, Sadecki T, Sadeghian L, Sakellariadou M, Salconi L, Saleem M, Zúñiga J, Salemi F, Samajdar A, Sammut L, Sampson L, Sanchez E, Sandberg V, Sanders J, Sassolas B, Sathyaprakash B, Saulson P, Aartsen M, Sauter O, Savage R, Sawadsky A, Schale P, Scheuer J, Schmidt E, Schmidt J, Schmidt P, Schnabel R, Schofield R, Ackermann M, Schönbeck A, Schreiber E, Schuette D, Schutz B, Schwalbe S, Scott J, Scott S, Sellers D, Sengupta A, Sentenac D, Adams J, Sequino V, Sergeev A, Setyawati Y, Shaddock D, Shaffer T, Shahriar M, Shapiro B, Shawhan P, Sheperd A, Shoemaker D, Aguilar J, Shoemaker D, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva A, Singer A, Singer L, Singh A, Singh R, Ahlers M, Singhal A, Sintes A, Slagmolen B, Smith B, Smith J, Smith R, Son E, Sorazu B, Sorrentino F, Souradeep T, Ahrens M, Spencer A, Srivastava A, Staley A, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stephens B, Stevenson S, Stone R, Al Samarai I, Strain K, Straniero N, Stratta G, Strigin S, Sturani R, Stuver A, Summerscales T, Sun L, Sunil S, Sutton P, Altmann D, Swinkels B, Szczepańczyk M, Tacca M, Talukder D, Tanner D, Tápai M, Taracchini A, Taylor R, Theeg T, Thomas E, Andeen K, Thomas M, Thomas P, Thorne K, Thrane E, Tippens T, Tiwari S, Tiwari V, Tokmakov K, Toland K, Tomlinson C, Anderson T, Tonelli M, Tornasi Z, Torrie C, Töyrä D, Travasso F, Traylor G, Trifirò D, Trinastic J, Tringali M, Trozzo L, Ansseau I, Tse M, Tso R, Turconi M, Tuyenbayev D, Ugolini D, Unnikrishnan C, Urban A, Usman S, Vahlbruch H, Vajente G, Anton G, Valdes G, van Bakel N, van Beuzekom M, van den Brand J, Van Den Broeck C, Vander-Hyde D, van der Schaaf L, van Heijningen J, van Veggel A, Vardaro M, Archinger M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch P, Venkateswara K, Venugopalan G, Verkindt D, Argüelles C, Vetrano F, Viceré A, Viets A, Vinciguerra S, Vine D, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Auffenberg J, Voss D, Vousden W, Vyatchanin S, Wade A, Wade L, Wade M, Walker M, Wallace L, Walsh S, Wang G, Axani S, Wang H, Wang M, Wang Y, Ward R, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Bagherpour H, Weinstein A, Weiss R, Wen L, Weßels P, Westphal T, Wette K, Whelan J, Whiting B, Whittle C, Williams D, Bai X, Williams R, Williamson A, Willis J, Willke B, Wimmer M, Winkler W, Wipf C, Wittel H, Woan G, Woehler J, Barwick S, Worden J, Wright J, Wu D, Wu G, Yam W, Yamamoto H, Yancey C, Yap M, Yu H, Yu H, Baum V, Yvert M, Zadrożny A, Zangrando L, Zanolin M, Zendri JP, Zevin M, Zhang L, Zhang M, Zhang T, Zhang Y, Bay R, Zhao C, Zhou M, Zhou Z, Zhu S, Zhu X, Zucker M, Zweizig J, Beatty J, Becker Tjus J, Becker KH, BenZvi S, Berley D, Bernardini E, Besson D, Binder G, Bindig D, Blaufuss E, Blot S, Bohm C, Börner M, Bos F, Bose D, Böser S, Botner O, Bradascio F, Braun J, Brayeur L, Bretz HP, Bron S, Burgman A, Carver T, Casier M, Cheung E, Chirkin D, Christov A, Clark K, Classen L, Coenders S, Collin G, Conrad J, Cowen D, Cross R, Day M, de André J, De Clercq C, del Pino Rosendo E, Dembinski H, De Ridder S, Desiati P, de Vries K, de Wasseige G, de With M, DeYoung T, Díaz-Vélez J, di Lorenzo V, Dujmovic H, Dumm J, Dunkman M, Eberhardt B, Ehrhardt T, Eichmann B, Eller P, Euler S, Evenson P, Fahey S, Fazely A, Feintzeig J, Felde J, Filimonov K, Finley C, Flis S, Fösig CC, Franckowiak A, Friedman E, Fuchs T, Gaisser T, Gallagher J, Gerhardt L, Ghorbani K, Giang W, Gladstone L, Glauch T, Glüsenkamp T, Goldschmidt A, Gonzalez J, Grant D, Griffith Z, Haack C, Hallgren A, Halzen F, Hansen E, Hansmann T, Hanson K, Hebecker D, Heereman D, Helbing K, Hellauer R, Hickford S, Hignight J, Hill G, Hoffman K, Hoffmann R, Hoshina K, Huang F, Huber M, Hultqvist K, In S, Ishihara A, Jacobi E, Japaridze G, Jeong M, Jero K, Jones B, Kang W, Kappes A, Karg T, Karle A, Katz U, Kauer M, Keivani A, Kelley J, Kheirandish A, Kim J, Kim M, Kintscher T, Kiryluk J, Kittler T, Klein S, Kohnen G, Koirala R, Kolanoski H, Konietz R, Köpke L, Kopper C, Kopper S, Koskinen D, Kowalski M, Krings K, Kroll M, Krückl G, Krüger C, Kunnen J, Kunwar S, Kurahashi N, Kuwabara T, Kyriacou A, Labare M, Lanfranchi J, Larson M, Lauber F, Lennarz D, Lesiak-Bzdak M, Leuermann M, Lu L, Lünemann J, Madsen J, Maggi G, Mahn K, Mancina S, Maruyama R, Mase K, Maunu R, McNally F, Meagher K, Medici M, Meier M, Menne T, Merino G, Meures T, Miarecki S, Micallef J, Momenté G, Montaruli T, Moulai M, Nahnhauer R, Naumann U, Neer G, Niederhausen H, Nowicki S, Nygren D, Obertacke Pollmann A, Olivas A, O’Murchadha A, Palczewski T, Pandya H, Pankova D, Peiffer P, Penek Ö, Pepper J, Pérez de los Heros C, Pieloth D, Pinat E, Price P, Przybylski G, Quinnan M, Raab C, Rädel L, Rameez M, Rawlins K, Reimann R, Relethford B, Relich M, Resconi E, Rhode W, Richman M, Riedel B, Robertson S, Rongen M, Rott C, Ruhe T, Ryckbosch D, Rysewyk D, Sabbatini L, Sanchez Herrera S, Sandrock A, Sandroos J, Sarkar S, Satalecka K, Schlunder P, Schmidt T, Schoenen S, Schöneberg S, Schumacher L, Seckel D, Seunarine S, Soldin D, Song M, Spiczak G, Spiering C, Stachurska J, Stanev T, Stasik A, Stettner J, Steuer A, Stezelberger T, Stokstad R, Stößl A, Ström R, Strotjohann N, Sullivan G, Sutherland M, Taavola H, Taboada I, Tatar J, Tenholt F, Ter-Antonyan S, Terliuk A, Tešić G, Tilav S, Toale P, Tobin M, Toscano S, Tosi D, Tselengidou M, Tung C, Turcati A, Unger E, Usner M, Vandenbroucke J, van Eijndhoven N, Vanheule S, van Rossem M, van Santen J, Vehring M, Voge M, Vogel E, Vraeghe M, Walck C, Wallace A, Wallraff M, Wandkowsky N, Waza A, Weaver C, Weiss M, Wendt C, Westerhoff S, Whelan B, Wickmann S, Wiebe K, Wiebusch C, Wille L, Williams D, Wills L, Wolf M, Wood T, Woolsey E, Woschnagg K, Xu D, Xu X, Xu Y, Yanez J, Yodh G, Yoshida S, Zoll M, Abbott B, Abbott R, Abbott T, Abernathy M, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari R, Adya V, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar O, Aiello L, Ain A, Ajith P, Allen B, Allocca A, Altin P, Ananyeva A, Anderson S, Anderson W, Appert S, Arai K, Araya M, Areeda J, Arnaud N, Arun K, Ascenzi S, Ashton G, Ast M, Aston S, Astone P, Aufmuth P, Aulbert C, Avila-Alvarez A, Babak S, Bacon P, Bader M, Baker P, Baldaccini F, Ballardin G, Ballmer S, Barayoga J, Barclay S, Barish B, Barker D, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch J, Baune C, Bavigadda V, Bazzan M, Beer C, Bejger M, Belahcene I, Belgin M, Bell A, Berger B, Bergmann G, Berry C, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko I, Billingsley G, Billman C, Birch J, Birney R, Birnholtz O, Biscans S, Bisht A, Bitossi M, Biwer C, Bizouard M, Blackburn J, Blackman J, Blair C, Blair D, Blair R, Bloemen S, Bock O, Boer M, Bogaert G, Bohe A, Bondu F, Bonnand R, Boom B, Bork R, Boschi V, Bose S, Bouffanais Y, Bozzi A, Bradaschia C, Brady P, Braginsky V, Branchesi M, Brau J, Briant T, Brillet A, Brinkmann M, Brisson V, Brockill P, Broida J, Brooks A, Brown D, Brown D, Brown N, Brunett S, Buchanan C, Buikema A, Bulik T, Bulten H, Buonanno A, Buskulic D, Buy C, Byer R, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister T, Calloni E, Camp J, Canepa M, Cannon K, Cao H, Cao J, Capano C, Capocasa E, Carbognani F, Caride S, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda C, Cerboni Baiardi L, Cerretani G, Cesarini E, Chamberlin S, Chan M, Chao S, Charlton P, Chassande-Mottin E, Cheeseboro B, Chen H, Chen Y, Cheng HP, Chincarini A, Chiummo A, Chmiel T, Cho H, Cho M, Chow J, Christensen N, Chu Q, Chua A, Chua S, Chung S, Ciani G, Clara F, Clark J, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Colla A, Collette C, Cominsky L, Constancio M, Conti L, Cooper S, Corbitt T, Cornish N, Corsi A, Cortese S, Costa C, Coughlin M, Coughlin S, Coulon JP, Countryman S, Couvares P, Covas P, Cowan E, Coward D, Cowart M, Coyne D, Coyne R, Creighton J, Creighton T, Cripe J, Crowder S, Cullen T, Cumming A, Cunningham L, Cuoco E, Dal Canton T, Danilishin S, D’Antonio S, Danzmann K, Dasgupta A, Da Silva Costa C, Dattilo V, Dave I, Davier M, Davies G, Davis D, Daw E, Day B, Day R, De S, DeBra D, Debreczeni G, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Denker T, Dent T, Dergachev V, De Rosa R, DeRosa R, DeSalvo R, Devine R, Dhurandhar S, Díaz M, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Di Pace S, Di Palma I, Di Virgilio A, Doctor Z, Dolique V, Donovan F, Dooley K, Doravari S, Dorrington I, Douglas R, Dovale Álvarez M, Downes T, Drago M, Drever R, Driggers J, Du Z, Ducrot M, Dwyer S, Edo T, Edwards M, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry S, Eisenstein R, Essick R, Etienne Z, Etzel T, Evans M, Evans T, Everett R, Factourovich M, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr W, Fauchon-Jones E, Favata M, Fays M, Fehrmann H, Fejer M, Fernández Galiana A, Ferrante I, Ferreira E, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fisher R, Flaminio R, Fletcher M, Fong H, Forsyth S, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fries E, Fritschel P, Frolov V, Fulda P, Fyffe M, Gabbard H, Gadre B, Gaebel S, Gair J, Gammaitoni L, Gaonkar S, Garufi F, Gaur G, Gayathri V, Gehrels N, Gemme G, Genin E, Gennai A, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giaime J, Giardina K, Giazotto A, Gill K, Glaefke A, Goetz E, Goetz R, Gondan L, González G, Gonzalez Castro J, Gopakumar A, Gorodetsky M, Gossan S, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Gray C, Greco G, Green A, Groot P, Grote H, Grunewald S, Guidi G, Guo X, Gupta A, Gupta M, Gushwa K, Gustafson E, Gustafson R, Hacker J, Hall B, Hall E, Hammond G, Haney M, Hanke M, Hanks J, Hanna C, Hannam M, Hanson J, Hardwick T, Harms J, Harry G, Harry I, Hart M, Hartman M, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze M, Heitmann H, Hello P, Hemming G, Hendry M, Heng I, Hennig J, Henry J, Heptonstall A, Heurs M, Hild S, Hoak D, Hofman D, Holt K, Holz D, Hopkins P, Hough J, Houston E, Howell E, Hu Y, Huerta E, Huet D, Hughey B, Husa S, Huttner S, Huynh-Dinh T, Indik N, Ingram D, Inta R, Isa H, Isac JM, Isi M, Isogai T, Iyer B, Izumi K, Jacqmin T, Jani K, Jaranowski P, Jawahar S, Jiménez-Forteza F, Johnson W, Jones D, Jones R, Jonker R, Ju L, Junker J, Kalaghatgi C, Kalogera V, Kandhasamy S, Kang G, Kanner J, Karki S, Karvinen K, Kasprzack M, Katsavounidis E, Katzman W, Kaufer S, Kaur T, Kawabe K, Kéfélian F, Keitel D, Kelley D, Kennedy R, Key J, Khalili F, Khan I, Khan S, Khan Z, Khazanov E, Kijbunchoo N, Kim C, Kim J, Kim W, Kim W, Kim YM, Kimbrell S, King E, King P, Kirchhoff R, Kissel J, Klein B, Kleybolte L, Klimenko S, Koch P, Koehlenbeck S, Koley S, Kondrashov V, Kontos A, Korobko M, Korth W, Kowalska I, Kozak D, Krämer C, Kringel V, Królak A, Kuehn G, Kumar P, Kumar R, Kuo L, Kutynia A, Lackey B, Landry M, Lang R, Lange J, Lantz B, Lanza R, Lartaux-Vollard A, Lasky P, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lebigot E, Lee C, Lee H, Lee H, Lee K, Lehmann J, Lenon A, Leonardi M, Leong J, Leroy N, Letendre N, Levin Y, Li T, Libson A, Littenberg T, Liu J, Lockerbie N, Lombardi A, London L, Lord J, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough J, Lovelace G, Lück H, Lundgren A, Lynch R, Ma Y, Macfoy S, Machenschalk B, MacInnis M, Macleod D, Magaña-Sandoval F, Majorana E, Maksimovic I, Malvezzi V, Man N, Mandic V, Mangano V, Mansell G, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markosyan A, Maros E, Martelli F, Martellini L, Martin I, Martynov D, Mason K, Masserot A, Massinger T, Masso-Reid M, Mastrogiovanni S, Matichard F, Matone L, Mavalvala N, Mazumder N, McCarthy R, McClelland D, McCormick S, McGrath C, McGuire S, McIntyre G. Search for high-energy neutrinos from gravitational wave event GW151226 and candidate LVT151012 with ANTARES and IceCube. Int J Clin Exp Med 2017. [DOI: 10.1103/physrevd.96.022005] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
31
|
Piga M, Congia M, Gabba A, Figus F, Floris A, Mathieu A, Cauli A. Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus. Lupus 2017; 27:190-198. [DOI: 10.1177/0961203317716319] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- M Piga
- Rheumatology Unit, University Clinic and AOU of Cagliari, Italy
| | - M Congia
- Rheumatology Unit, University Clinic and AOU of Cagliari, Italy
| | - A Gabba
- Rheumatology Unit, University Clinic and AOU of Cagliari, Italy
| | - F Figus
- Rheumatology Unit, University Clinic and AOU of Cagliari, Italy
| | - A Floris
- Rheumatology Unit, University Clinic and AOU of Cagliari, Italy
| | - A Mathieu
- Rheumatology Unit, University Clinic and AOU of Cagliari, Italy
| | - A Cauli
- Rheumatology Unit, University Clinic and AOU of Cagliari, Italy
| |
Collapse
|
32
|
Garrigues P, Su C, Navarro M, Paillous P, Janin C, Mathieu A. Hypomagnésémie induite par les inhibiteurs de la pompe à protons : un trouble métabolique à ne pas méconnaître. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Rossini M, Viapiana O, Vitiello M, Malavolta N, La Montagna G, Maddali Bongi S, Di Munno O, Nuti R, Manzini C, Ferri C, Bogliolo L, Mathieu A, Cantatore F, Del Puente A, Muratore M, Grassi W, Frediani B, Saviola G, Delvino P, Mirone L, Ferraccioli G, Tripi G, Piazza I, Gatti D. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Reumatismo 2017; 69:30-39. [DOI: 10.4081/reumatismo.2017.922] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2016] [Revised: 04/02/2017] [Accepted: 04/05/2017] [Indexed: 11/22/2022] Open
Abstract
Osteoporosis and fractures are common and invalidating consequences of chronic glucorticoid (GC) treatment. Reliable information regarding the epidemiology of GC induced osteoporosis (GIOP) comes exclusively from the placebo group of randomized clinical trials while observational studies are generally lacking data on the real prevalence of vertebral fractures, GC dosage and primary diagnosis. The objective of this study was to evaluate the prevalence and incidence of osteoporotic fractures and to identify their major determinants (primary disease, GC dosage, bone mineral density, risk factors, specific treatment for GIOP) in a large cohort of consecutive patients aged >21 years, on chronic treatment with GC (≥5 mg prednisone - PN - equivalent) and attending rheumatology centers located all over Italy. Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) is a national multicenter cross-sectional and longitudinal observational study. 553 patients suffering from Rheumatoid Arthritis (RA), Polymyalgia Rheumatica (PMR) and Connective Tissue Diseases (CTDs) and in chronic treatment with GCs were enrolled. Osteoporotic BMD values (T score <-2.5) were observed in 28%, 38% and 35% of patients with CTDs, PMR or RA at the lumbar spine, and in 18%, 29% and 26% at the femoral neck, respectively. Before GC treatment, prevalent clinical fractures were reported by 12%, 37% and 17% of patients with CTDs, PMR, or RA, respectively. New clinical fragility fractures during GC treatment were reported by 12%, 10% and 23% of CTDs, PMR and RA patients, respectively. Vertebral fractures were the prevailing type of fragility fracture. More than 30% of patients had recurrence of fracture. An average of 80% of patients were in supplementation with calcium and/or vitamin D during treatment with GCs. Respectively, 64%, 80%, and 72% of the CTDs, PMR and RA patients were on pharmacological treatment for GIOP, almost exclusively with bisphosphonates. The GIOTTO study might provide relevant contributions to clinical practice, in particular by highlighting and quantifying in real life the prevalence of GIOP and relative fractures, the frequency of the main risk factors, and the currently sub-optimal prevention. Moreover, these results emphasize the importance of the underlying rheumatic disease on the risk of GIOP associated fractures.
Collapse
|
34
|
André M, Caballé A, van der Schaar M, Solsona A, Houégnigan L, Zaugg S, Sánchez AM, Castell JV, Solé M, Vila F, Djokic D, Adrián-Martínez S, Albert A, Anghinolfi M, Anton G, Ardid M, Aubert JJ, Avgitas T, Baret B, Barrios-Martí J, Basa S, Bertin V, Biagi S, Bormuth R, Bouwhuis MC, Bruijn R, Brunner J, Busto J, Capone A, Caramete L, Carr J, Celli S, Chiarusi T, Circella M, Coleiro A, Coniglione R, Costantini H, Coyle P, Creusot A, Deschamps A, De Bonis G, Distefano C, Di Palma I, Donzaud C, Dornic D, Drouhin D, Eberl T, El Bojaddaini I, Elsässer D, Enzenhöfer A, Fehn K, Felis I, Fusco LA, Galatà S, Gay P, Geißelsöder S, Geyer K, Giordano V, Gleixner A, Glotin H, Gracia-Ruiz R, Graf K, Hallmann S, van Haren H, Heijboer AJ, Hello Y, Hernandez-Rey JJ, Hößl J, Hofestädt J, Hugon C, Illuminati G, James CW, de Jong M, Jongen M, Kadler M, Kalekin O, Katz U, Kießling D, Kouchner A, Kreter M, Kreykenbohm I, Kulikovskiy V, Lachaud C, Lahmann R, Lefèvre D, Leonora E, Loucatos S, Marcelin M, Margiotta A, Marinelli A, Martínez-Mora JA, Mathieu A, Melis K, Michael T, Migliozzi P, Moussa A, Mueller C, Nezri E, Păvălaş GE, Pellegrino C, Perrina C, Piattelli P, Popa V, Pradier T, Racca C, Riccobene G, Roensch K, Saldaña M, Samtleben DFE, Sanguineti M, Sapienza P, Schnabel J, Schüssler F, Seitz T, Sieger C, Spurio M, Stolarczyk T, Sánchez-Losa A, Taiuti M, Trovato A, Tselengidou M, Turpin D, Tönnis C, Vallage B, Vallée C, Van Elewyck V, Vivolo D, Wagner S, Wilms J, Zornoza JD, Zuñiga J. Sperm whale long-range echolocation sounds revealed by ANTARES, a deep-sea neutrino telescope. Sci Rep 2017; 7:45517. [PMID: 28401960 PMCID: PMC5388847 DOI: 10.1038/srep45517] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2016] [Accepted: 02/14/2017] [Indexed: 11/09/2022] Open
Abstract
Despite dedicated research has been carried out to adequately map the distribution of the sperm whale in the Mediterranean Sea, unlike other regions of the world, the species population status is still presently uncertain. The analysis of two years of continuous acoustic data provided by the ANTARES neutrino telescope revealed the year-round presence of sperm whales in the Ligurian Sea, probably associated with the availability of cephalopods in the region. The presence of the Ligurian Sea sperm whales was demonstrated through the real-time analysis of audio data streamed from a cabled-to-shore deep-sea observatory that allowed the hourly tracking of their long-range echolocation behaviour on the Internet. Interestingly, the same acoustic analysis indicated that the occurrence of surface shipping noise would apparently not condition the foraging behaviour of the sperm whale in the area, since shipping noise was almost always present when sperm whales were acoustically detected. The continuous presence of the sperm whale in the region confirms the ecological value of the Ligurian sea and the importance of ANTARES to help monitoring its ecosystems.
Collapse
Affiliation(s)
- M André
- Technical University of Catalonia, BarcelonaTech (UPC), Laboratory of Applied Bioacoustics (LAB), Rambla Exposició, 24, 08800 Vilanova i la Geltru, Barcelona, Spain
| | - A Caballé
- Technical University of Catalonia, BarcelonaTech (UPC), Laboratory of Applied Bioacoustics (LAB), Rambla Exposició, 24, 08800 Vilanova i la Geltru, Barcelona, Spain
| | - M van der Schaar
- Technical University of Catalonia, BarcelonaTech (UPC), Laboratory of Applied Bioacoustics (LAB), Rambla Exposició, 24, 08800 Vilanova i la Geltru, Barcelona, Spain
| | - A Solsona
- Technical University of Catalonia, BarcelonaTech (UPC), Laboratory of Applied Bioacoustics (LAB), Rambla Exposició, 24, 08800 Vilanova i la Geltru, Barcelona, Spain
| | - L Houégnigan
- Technical University of Catalonia, BarcelonaTech (UPC), Laboratory of Applied Bioacoustics (LAB), Rambla Exposició, 24, 08800 Vilanova i la Geltru, Barcelona, Spain
| | - S Zaugg
- Technical University of Catalonia, BarcelonaTech (UPC), Laboratory of Applied Bioacoustics (LAB), Rambla Exposició, 24, 08800 Vilanova i la Geltru, Barcelona, Spain
| | - A M Sánchez
- Technical University of Catalonia, BarcelonaTech (UPC), Laboratory of Applied Bioacoustics (LAB), Rambla Exposició, 24, 08800 Vilanova i la Geltru, Barcelona, Spain
| | - J V Castell
- Technical University of Catalonia, BarcelonaTech (UPC), Laboratory of Applied Bioacoustics (LAB), Rambla Exposició, 24, 08800 Vilanova i la Geltru, Barcelona, Spain
| | - M Solé
- Technical University of Catalonia, BarcelonaTech (UPC), Laboratory of Applied Bioacoustics (LAB), Rambla Exposició, 24, 08800 Vilanova i la Geltru, Barcelona, Spain
| | - F Vila
- Technical University of Catalonia, BarcelonaTech (UPC), Laboratory of Applied Bioacoustics (LAB), Rambla Exposició, 24, 08800 Vilanova i la Geltru, Barcelona, Spain
| | - D Djokic
- Technical University of Catalonia, BarcelonaTech (UPC), Laboratory of Applied Bioacoustics (LAB), Rambla Exposició, 24, 08800 Vilanova i la Geltru, Barcelona, Spain
| | - S Adrián-Martínez
- Institut d'Investigació per a la Gestió Integrada de les Zones Costaneres (IGIC) - Universitat Politècnica de Valencia, C/Paranimf 1, 46730 Gandia, Spain
| | - A Albert
- GRPHE - Université de Haute Alsace - Institut universitaire de technologie de Colmar, 34 rue du Grillenbreit BP 50568 - 68008, Colmar, France
| | - M Anghinolfi
- INFN - Sezione di Genova, Via Dodecaneso 33, 16146 Genova, Italy
| | - G Anton
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - M Ardid
- Institut d'Investigació per a la Gestió Integrada de les Zones Costaneres (IGIC) - Universitat Politècnica de Valencia, C/Paranimf 1, 46730 Gandia, Spain
| | - J-J Aubert
- Aix-Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - T Avgitas
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/IRFU, Observatoire de Paris, Sorbonne Paris Cité, 75205 Paris, France
| | - B Baret
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/IRFU, Observatoire de Paris, Sorbonne Paris Cité, 75205 Paris, France
| | - J Barrios-Martí
- IFIC - Institut de Física Corpuscular (CSIC - Universitat de València) c/Catedrático José Beltran, 2 E-46980 Paterna, Valencia, Spain
| | - S Basa
- LAM - Laboratoire d'Astrophysique de Marseille, Pôle de l'Etoile Site de Château-Gombert, rue Frédéric Joliot-Curie 38, 13388 Marseille Cédex 13, France
| | - V Bertin
- Aix-Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - S Biagi
- INFN - Laboratori Nazionali del Sud (LNS), Via S. So a 62, 95123 Catania, Italy
| | - R Bormuth
- Nikhef, Science Park, Amsterdam, The Netherlands.,Huygens-Kamerlingh Onnes Laboratorium, Universiteit Leiden, The Netherlands
| | - M C Bouwhuis
- Nikhef, Science Park, Amsterdam, The Netherlands
| | - R Bruijn
- Nikhef, Science Park, Amsterdam, The Netherlands.,Universiteit van Amsterdam, Instituut voor Hoge-Energie Fysica, Science Park 105, 1098 XG Amsterdam, The Netherlands
| | - J Brunner
- Aix-Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - J Busto
- Aix-Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - A Capone
- INFN -Sezione di Roma, P.le Aldo Moro 2, 00185 Roma, Italy.,Dipartimento di Fisica dell'Universita La Sapienza, P.le Aldo Moro 2, 00185 Roma, Italy
| | - L Caramete
- Institute for Space Science, RO-077125 Bucharest, Magurele, Romania
| | - J Carr
- Aix-Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - S Celli
- INFN -Sezione di Roma, P.le Aldo Moro 2, 00185 Roma, Italy.,Dipartimento di Fisica dell'Universita La Sapienza, P.le Aldo Moro 2, 00185 Roma, Italy
| | - T Chiarusi
- INFN - Sezione di Bologna, Viale Berti-Pichat 6/2, 40127 Bologna, Italy
| | - M Circella
- INFN - Sezione di Bari, Via E. Orabona 4, 70126 Bari, Italy
| | - A Coleiro
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/IRFU, Observatoire de Paris, Sorbonne Paris Cité, 75205 Paris, France
| | - R Coniglione
- INFN - Laboratori Nazionali del Sud (LNS), Via S. So a 62, 95123 Catania, Italy
| | - H Costantini
- Aix-Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - P Coyle
- Aix-Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - A Creusot
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/IRFU, Observatoire de Paris, Sorbonne Paris Cité, 75205 Paris, France
| | - A Deschamps
- Geoazur, UCA, CNRS, IRD, Observatoire de la Côte d'Azur, Sophia Antipolis, France
| | - G De Bonis
- INFN -Sezione di Roma, P.le Aldo Moro 2, 00185 Roma, Italy.,Dipartimento di Fisica dell'Universita La Sapienza, P.le Aldo Moro 2, 00185 Roma, Italy
| | - C Distefano
- INFN - Laboratori Nazionali del Sud (LNS), Via S. So a 62, 95123 Catania, Italy
| | - I Di Palma
- INFN -Sezione di Roma, P.le Aldo Moro 2, 00185 Roma, Italy.,Dipartimento di Fisica dell'Universita La Sapienza, P.le Aldo Moro 2, 00185 Roma, Italy
| | - C Donzaud
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/IRFU, Observatoire de Paris, Sorbonne Paris Cité, 75205 Paris, France.,Univ. Paris-Sud, 91405 Orsay Cedex, France
| | - D Dornic
- Aix-Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - D Drouhin
- GRPHE - Université de Haute Alsace - Institut universitaire de technologie de Colmar, 34 rue du Grillenbreit BP 50568 - 68008, Colmar, France
| | - T Eberl
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - I El Bojaddaini
- University Mohammed I, Laboratory of Physics of Matter and Radiations, B.P.717, Oujda 6000, Morocco
| | - D Elsässer
- Institut für Theoretische Physik und Astrophysik, Universität Wärzburg, Emil-Fischer Str. 31, 97074 Würzburg, Germany
| | - A Enzenhöfer
- Aix-Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - K Fehn
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - I Felis
- Institut d'Investigació per a la Gestió Integrada de les Zones Costaneres (IGIC) - Universitat Politècnica de Valencia, C/Paranimf 1, 46730 Gandia, Spain
| | - L A Fusco
- INFN - Sezione di Bologna, Viale Berti-Pichat 6/2, 40127 Bologna, Italy.,Dipartimento di Fisica e Astronomia dell'Universita, Viale Berti Pichat 6/2, 40127 Bologna, Italy
| | - S Galatà
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/IRFU, Observatoire de Paris, Sorbonne Paris Cité, 75205 Paris, France
| | - P Gay
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/IRFU, Observatoire de Paris, Sorbonne Paris Cité, 75205 Paris, France.,Laboratoire de Physique Corpusculaire, Clermont Université, Université Blaise Pascal, CNRS/IN2P3, BP 10448, F-63000 Clermont-Ferrand, France
| | - S Geißelsöder
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - K Geyer
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - V Giordano
- INFN - Sezione di Catania, Viale Andrea Doria 6, 95125 Catania, Italy
| | - A Gleixner
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - H Glotin
- LSIS, Aix Marseille Université CNRS ENSAM LSIS UMR 7296 13397 Marseille, France.,Université de Toulon CNRS LSIS UMR 7296 83957 La Garde, France.,Institut universitaire de France, 75005 Paris, France
| | - R Gracia-Ruiz
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/IRFU, Observatoire de Paris, Sorbonne Paris Cité, 75205 Paris, France
| | - K Graf
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - S Hallmann
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - H van Haren
- Royal Netherlands Institute for Sea Research (NIOZ), Landsdiep 4, 1797 SZ 't Horntje (Texel), The Netherlands
| | - A J Heijboer
- Nikhef, Science Park, Amsterdam, The Netherlands
| | - Y Hello
- Geoazur, UCA, CNRS, IRD, Observatoire de la Côte d'Azur, Sophia Antipolis, France
| | - J J Hernandez-Rey
- IFIC - Institut de Física Corpuscular (CSIC - Universitat de València) c/Catedrático José Beltran, 2 E-46980 Paterna, Valencia, Spain
| | - J Hößl
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - J Hofestädt
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - C Hugon
- INFN - Sezione di Genova, Via Dodecaneso 33, 16146 Genova, Italy.,Dipartimento di Fisica dell'Universita, Via Dodecaneso 33, 16146 Genova, Italy
| | - G Illuminati
- IFIC - Institut de Física Corpuscular (CSIC - Universitat de València) c/Catedrático José Beltran, 2 E-46980 Paterna, Valencia, Spain.,INFN -Sezione di Roma, P.le Aldo Moro 2, 00185 Roma, Italy.,Dipartimento di Fisica dell'Universita La Sapienza, P.le Aldo Moro 2, 00185 Roma, Italy
| | - C W James
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - M de Jong
- Nikhef, Science Park, Amsterdam, The Netherlands.,Huygens-Kamerlingh Onnes Laboratorium, Universiteit Leiden, The Netherlands
| | - M Jongen
- Nikhef, Science Park, Amsterdam, The Netherlands
| | - M Kadler
- Institut für Theoretische Physik und Astrophysik, Universität Wärzburg, Emil-Fischer Str. 31, 97074 Würzburg, Germany
| | - O Kalekin
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - U Katz
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - D Kießling
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - A Kouchner
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/IRFU, Observatoire de Paris, Sorbonne Paris Cité, 75205 Paris, France.,LSIS, Aix Marseille Université CNRS ENSAM LSIS UMR 7296 13397 Marseille, France.,Université de Toulon CNRS LSIS UMR 7296 83957 La Garde, France.,Institut universitaire de France, 75005 Paris, France
| | - M Kreter
- Institut für Theoretische Physik und Astrophysik, Universität Wärzburg, Emil-Fischer Str. 31, 97074 Würzburg, Germany
| | - I Kreykenbohm
- Dr. Remeis-Sternwarte and ECAP, Universitat Erlangen-Nurnberg, Sternwartstr. 7, 96049 Bamberg, Germany
| | - V Kulikovskiy
- INFN - Laboratori Nazionali del Sud (LNS), Via S. So a 62, 95123 Catania, Italy.,Moscow State University, Skobeltsyn Institute of Nuclear Physics, Leninskie gory, 119991 Moscow, Russia
| | - C Lachaud
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/IRFU, Observatoire de Paris, Sorbonne Paris Cité, 75205 Paris, France
| | - R Lahmann
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - D Lefèvre
- Mediterranean Institute of Oceanography (MIO), Aix-Marseille University, 13288, Marseille, Cédex 9, France.,Université du Sud Toulon-Var, 83957 CNRS-INSU/IRD UM 110, La Garde Cédex, France
| | - E Leonora
- INFN - Sezione di Catania, Viale Andrea Doria 6, 95125 Catania, Italy.,Dipartimento di Fisica ed Astronomia dell'Universita, Viale Andrea Doria 6, 95125 Catania, Italy
| | - S Loucatos
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/IRFU, Observatoire de Paris, Sorbonne Paris Cité, 75205 Paris, France.,Direction des Sciences de la Matière - Institut de recherche sur les lois fondamentales de l'Univers - Service de Physique des Particules, CEA Saclay, 91191 Gif-sur-Yvette Cédex, France
| | - M Marcelin
- LAM - Laboratoire d'Astrophysique de Marseille, Pôle de l'Etoile Site de Château-Gombert, rue Frédéric Joliot-Curie 38, 13388 Marseille Cédex 13, France
| | - A Margiotta
- INFN - Sezione di Bologna, Viale Berti-Pichat 6/2, 40127 Bologna, Italy.,Dipartimento di Fisica e Astronomia dell'Universita, Viale Berti Pichat 6/2, 40127 Bologna, Italy
| | - A Marinelli
- INFN - Sezione di Pisa, Largo B. Pontecorvo 3, 56127 Pisa, Italy.,Dipartimento di Fisica dell'Universita, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - J A Martínez-Mora
- Institut d'Investigació per a la Gestió Integrada de les Zones Costaneres (IGIC) - Universitat Politècnica de Valencia, C/Paranimf 1, 46730 Gandia, Spain
| | - A Mathieu
- Aix-Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - K Melis
- Nikhef, Science Park, Amsterdam, The Netherlands.,Universiteit van Amsterdam, Instituut voor Hoge-Energie Fysica, Science Park 105, 1098 XG Amsterdam, The Netherlands
| | - T Michael
- Nikhef, Science Park, Amsterdam, The Netherlands
| | - P Migliozzi
- INFN -Sezione di Napoli, Via Cintia 80126 Napoli, Italy
| | - A Moussa
- University Mohammed I, Laboratory of Physics of Matter and Radiations, B.P.717, Oujda 6000, Morocco
| | - C Mueller
- Institut für Theoretische Physik und Astrophysik, Universität Wärzburg, Emil-Fischer Str. 31, 97074 Würzburg, Germany
| | - E Nezri
- LAM - Laboratoire d'Astrophysique de Marseille, Pôle de l'Etoile Site de Château-Gombert, rue Frédéric Joliot-Curie 38, 13388 Marseille Cédex 13, France
| | - G E Păvălaş
- Institute for Space Science, RO-077125 Bucharest, Magurele, Romania
| | - C Pellegrino
- INFN - Sezione di Bologna, Viale Berti-Pichat 6/2, 40127 Bologna, Italy.,Dipartimento di Fisica e Astronomia dell'Universita, Viale Berti Pichat 6/2, 40127 Bologna, Italy
| | - C Perrina
- INFN -Sezione di Roma, P.le Aldo Moro 2, 00185 Roma, Italy.,Dipartimento di Fisica dell'Universita La Sapienza, P.le Aldo Moro 2, 00185 Roma, Italy
| | - P Piattelli
- INFN - Laboratori Nazionali del Sud (LNS), Via S. So a 62, 95123 Catania, Italy
| | - V Popa
- Institute for Space Science, RO-077125 Bucharest, Magurele, Romania
| | - T Pradier
- Université de Strasbourg, IPHC, 23 rue du Loess 67037 Strasbourg, France.,CNRS, UMR7178, 67037 Strasbourg, France
| | - C Racca
- GRPHE - Université de Haute Alsace - Institut universitaire de technologie de Colmar, 34 rue du Grillenbreit BP 50568 - 68008, Colmar, France
| | - G Riccobene
- INFN - Laboratori Nazionali del Sud (LNS), Via S. So a 62, 95123 Catania, Italy
| | - K Roensch
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - M Saldaña
- Institut d'Investigació per a la Gestió Integrada de les Zones Costaneres (IGIC) - Universitat Politècnica de Valencia, C/Paranimf 1, 46730 Gandia, Spain
| | - D F E Samtleben
- Nikhef, Science Park, Amsterdam, The Netherlands.,Huygens-Kamerlingh Onnes Laboratorium, Universiteit Leiden, The Netherlands
| | - M Sanguineti
- INFN - Sezione di Genova, Via Dodecaneso 33, 16146 Genova, Italy.,Dipartimento di Fisica dell'Universita, Via Dodecaneso 33, 16146 Genova, Italy
| | - P Sapienza
- INFN - Laboratori Nazionali del Sud (LNS), Via S. So a 62, 95123 Catania, Italy
| | - J Schnabel
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - F Schüssler
- Direction des Sciences de la Matière - Institut de recherche sur les lois fondamentales de l'Univers - Service de Physique des Particules, CEA Saclay, 91191 Gif-sur-Yvette Cédex, France
| | - T Seitz
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - C Sieger
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - M Spurio
- INFN - Sezione di Bologna, Viale Berti-Pichat 6/2, 40127 Bologna, Italy.,Dipartimento di Fisica e Astronomia dell'Universita, Viale Berti Pichat 6/2, 40127 Bologna, Italy
| | - Th Stolarczyk
- Direction des Sciences de la Matière - Institut de recherche sur les lois fondamentales de l'Univers - Service de Physique des Particules, CEA Saclay, 91191 Gif-sur-Yvette Cédex, France
| | - A Sánchez-Losa
- INFN - Laboratori Nazionali del Sud (LNS), Via S. So a 62, 95123 Catania, Italy.,INFN - Sezione di Bari, Via E. Orabona 4, 70126 Bari, Italy
| | - M Taiuti
- INFN - Sezione di Genova, Via Dodecaneso 33, 16146 Genova, Italy.,Dipartimento di Fisica dell'Universita, Via Dodecaneso 33, 16146 Genova, Italy
| | - A Trovato
- INFN - Laboratori Nazionali del Sud (LNS), Via S. So a 62, 95123 Catania, Italy
| | - M Tselengidou
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - D Turpin
- Aix-Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - C Tönnis
- IFIC - Institut de Física Corpuscular (CSIC - Universitat de València) c/Catedrático José Beltran, 2 E-46980 Paterna, Valencia, Spain
| | - B Vallage
- Technical University of Catalonia, BarcelonaTech (UPC), Laboratory of Applied Bioacoustics (LAB), Rambla Exposició, 24, 08800 Vilanova i la Geltru, Barcelona, Spain.,Direction des Sciences de la Matière - Institut de recherche sur les lois fondamentales de l'Univers - Service de Physique des Particules, CEA Saclay, 91191 Gif-sur-Yvette Cédex, France
| | - C Vallée
- Aix-Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - V Van Elewyck
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/IRFU, Observatoire de Paris, Sorbonne Paris Cité, 75205 Paris, France
| | - D Vivolo
- INFN -Sezione di Napoli, Via Cintia 80126 Napoli, Italy.,Dipartimento di Fisica dell'Universita Federico II di Napoli, Via Cintia 80126, Napoli, Italy
| | - S Wagner
- Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen Centre for Astroparticle Physics, Erwin-Rommel-Str. 1, 91058 Erlangen, Germany
| | - J Wilms
- Dr. Remeis-Sternwarte and ECAP, Universitat Erlangen-Nurnberg, Sternwartstr. 7, 96049 Bamberg, Germany
| | - J D Zornoza
- IFIC - Institut de Física Corpuscular (CSIC - Universitat de València) c/Catedrático José Beltran, 2 E-46980 Paterna, Valencia, Spain
| | - J Zuñiga
- IFIC - Institut de Física Corpuscular (CSIC - Universitat de València) c/Catedrático José Beltran, 2 E-46980 Paterna, Valencia, Spain
| |
Collapse
|
35
|
Mercati O, Huguet G, Danckaert A, André-Leroux G, Maruani A, Bellinzoni M, Rolland T, Gouder L, Mathieu A, Buratti J, Amsellem F, Benabou M, Van-Gils J, Beggiato A, Konyukh M, Bourgeois JP, Gazzellone MJ, Yuen RKC, Walker S, Delépine M, Boland A, Régnault B, Francois M, Van Den Abbeele T, Mosca-Boidron AL, Faivre L, Shimoda Y, Watanabe K, Bonneau D, Rastam M, Leboyer M, Scherer SW, Gillberg C, Delorme R, Cloëz-Tayarani I, Bourgeron T. CNTN6 mutations are risk factors for abnormal auditory sensory perception in autism spectrum disorders. Mol Psychiatry 2017; 22:625-633. [PMID: 27166760 PMCID: PMC5378808 DOI: 10.1038/mp.2016.61] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Revised: 02/12/2016] [Accepted: 02/17/2016] [Indexed: 12/11/2022]
Abstract
Contactin genes CNTN5 and CNTN6 code for neuronal cell adhesion molecules that promote neurite outgrowth in sensory-motor neuronal pathways. Mutations of CNTN5 and CNTN6 have previously been reported in individuals with autism spectrum disorders (ASDs), but very little is known on their prevalence and clinical impact. In this study, we identified CNTN5 and CNTN6 deleterious variants in individuals with ASD. Among the carriers, a girl with ASD and attention-deficit/hyperactivity disorder was carrying five copies of CNTN5. For CNTN6, both deletions (6/1534 ASD vs 1/8936 controls; P=0.00006) and private coding sequence variants (18/501 ASD vs 535/33480 controls; P=0.0005) were enriched in individuals with ASD. Among the rare CNTN6 variants, two deletions were transmitted by fathers diagnosed with ASD, one stop mutation CNTN6W923X was transmitted by a mother to her two sons with ASD and one variant CNTN6P770L was found de novo in a boy with ASD. Clinical investigations of the patients carrying CNTN5 or CNTN6 variants showed that they were hypersensitive to sounds (a condition called hyperacusis) and displayed changes in wave latency within the auditory pathway. These results reinforce the hypothesis of abnormal neuronal connectivity in the pathophysiology of ASD and shed new light on the genes that increase risk for abnormal sensory perception in ASD.
Collapse
Affiliation(s)
- O Mercati
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - G Huguet
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - A Danckaert
- Imagopole, Citech, Institut Pasteur, Paris, France
| | - G André-Leroux
- Institut Pasteur, Unité de Microbiologie Structurale, Paris, France
- CNRS UMR 3528, Paris, France
- INRA, Unité MaIAGE, UR1404, Jouy-en-Josas, France
| | - A Maruani
- Assistance Publique-Hôpitaux de Paris, Child and Adolescent Psychiatry Department, Robert Debré Hospital, Paris, France
| | - M Bellinzoni
- Institut Pasteur, Unité de Microbiologie Structurale, Paris, France
- CNRS UMR 3528, Paris, France
| | - T Rolland
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - L Gouder
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - A Mathieu
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - J Buratti
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - F Amsellem
- Assistance Publique-Hôpitaux de Paris, Child and Adolescent Psychiatry Department, Robert Debré Hospital, Paris, France
| | - M Benabou
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - J Van-Gils
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - A Beggiato
- Assistance Publique-Hôpitaux de Paris, Child and Adolescent Psychiatry Department, Robert Debré Hospital, Paris, France
| | - M Konyukh
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - J-P Bourgeois
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - M J Gazzellone
- Centre for Applied Genomics, Program in Genetics and Genome Biology, Hospital for Sick Children, Toronto, ON, Canada
| | - R K C Yuen
- Centre for Applied Genomics, Program in Genetics and Genome Biology, Hospital for Sick Children, Toronto, ON, Canada
| | - S Walker
- Centre for Applied Genomics, Program in Genetics and Genome Biology, Hospital for Sick Children, Toronto, ON, Canada
| | - M Delépine
- Centre National de Génotypage, Evry, France
| | - A Boland
- Centre National de Génotypage, Evry, France
| | - B Régnault
- Eukaryote Genotyping Platform, Genopole, Institut Pasteur, Paris, France
| | - M Francois
- Assistance Publique-Hôpitaux de Paris, ENT and Head and Neck Surgery Department, Robert Debré Hospital, Paris-VII University, Paris, France
| | - T Van Den Abbeele
- Assistance Publique-Hôpitaux de Paris, ENT and Head and Neck Surgery Department, Robert Debré Hospital, Paris-VII University, Paris, France
| | - A L Mosca-Boidron
- Département de Génétique, CHU Dijon et Université de Bourgogne, Dijon, France
| | - L Faivre
- Département de Génétique, CHU Dijon et Université de Bourgogne, Dijon, France
| | - Y Shimoda
- Department of Bioengineering, Nagaoka University of Technology, Nagaoka, Japan
| | - K Watanabe
- Department of Bioengineering, Nagaoka University of Technology, Nagaoka, Japan
| | - D Bonneau
- Département de Biochimie et Génétique, Centre Hospitalier Universitaire, Angers, France
| | - M Rastam
- Department of Clinical Sciences in Lund, Lund University, Lund, Sweden
- Gillberg Neuropsychiatry Centre, University of Gothenburg, Gothenburg, Sweden
| | - M Leboyer
- INSERM U955, Psychiatrie Translationnelle, Créteil, France
- Université Paris Est, Faculté de Médecine, Créteil, France
- Assistance Publique-Hôpitaux de Paris, DHU Pe-PSY, H. Mondor Hospital, Department of Psychiatry, Créteil, France
- FondaMental Foundation, Créteil, France
| | - S W Scherer
- Centre for Applied Genomics, Program in Genetics and Genome Biology, Hospital for Sick Children, Toronto, ON, Canada
- McLaughlin Centre, Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
| | - C Gillberg
- Gillberg Neuropsychiatry Centre, University of Gothenburg, Gothenburg, Sweden
| | - R Delorme
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
- Assistance Publique-Hôpitaux de Paris, Child and Adolescent Psychiatry Department, Robert Debré Hospital, Paris, France
| | - I Cloëz-Tayarani
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
| | - T Bourgeron
- Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France
- CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Paris, France
- Gillberg Neuropsychiatry Centre, University of Gothenburg, Gothenburg, Sweden
- FondaMental Foundation, Créteil, France
| |
Collapse
|
36
|
Garrigues P, de Roux T, Georgilopoulos E, Wanono E, Mathieu A. [Reactive arthritis due to Clostridium difficile: Report of two cases and literature review]. Rev Med Interne 2017; 38:551-554. [PMID: 28129954 DOI: 10.1016/j.revmed.2016.12.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Revised: 10/11/2016] [Accepted: 12/20/2016] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Reactive arthritis due to Clostridium difficile infection is uncommon. CASE REPORTS We report two cases of reactive arthritis associated with C. difficile infection that occurred in a 40-year-old woman and a 47-year-old man. The literature review between 1976 (date of first reported case) and 2016 retrieved 54 observations (including our two cases). Reactive arthritis occurs most frequently in young subjects after a variable time frame according to C. difficile infection, involving one or several articulations. The issue is generally favourable with or without anti-inflammatory treatment. CONCLUSION The increasing incidence of C. difficile infection makes more likely the occurrence of this related reactive arthritis. Therefore physicians should consider it in differential diagnosis of bacterial infections capable of causing reactive arthritis.
Collapse
Affiliation(s)
- P Garrigues
- Service de médecine interne, institut hospitalier Franco-Britannique, 92300 Levallois-Perret, France.
| | - T de Roux
- Service de médecine interne, institut hospitalier Franco-Britannique, 92300 Levallois-Perret, France
| | - E Georgilopoulos
- Service de médecine interne, institut hospitalier Franco-Britannique, 92300 Levallois-Perret, France
| | - E Wanono
- Service de médecine interne, institut hospitalier Franco-Britannique, 92300 Levallois-Perret, France
| | - A Mathieu
- Service de médecine interne, institut hospitalier Franco-Britannique, 92300 Levallois-Perret, France
| |
Collapse
|
37
|
Pani D, Piga M, Barabino G, Crabolu M, Uras S, Mathieu A, Raffo L. Home tele-rehabilitation for rheumatic patients: impact and satisfaction of care analysis. J Telemed Telecare 2016; 23:292-300. [DOI: 10.1177/1357633x16632950] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Introduction In this paper, we evaluated patients’ perspectives on the use of a system for home tele-rehabilitation, designed for subjects with low computer literacy suffering hand impairment due to rheumatic diseases. Methods After a clinical trial assessing device effectiveness, the Psychosocial Impact of Assistive Devices Scale (PIADS), Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) and Individually Prioritised Problem Assessment (IPPA) questionnaires were administered to evaluate the system’s impact on each patient’s life, and the results were correlated with clinical indices. Patients were asked to continue self-administered rehabilitation with common objects. One year later, a semi-structured telephone interview gathered data on their experience. Results The system received a positive QUEST score (4.5 ± 0.3) and a modest PIADS score (0.84 ± 0.8) due to the small impact on adaptability and self-esteem. The IPPA (3.7 ± 3.4) revealed improvement in the ability to perform tasks considered important, which was significantly correlated ( r = 0.60; p < 0.02) with the clinical Health Assessment Questionnaire (HAQ) index improvement. The interviews revealed a positive engagement effect, enhanced by the need to develop skills to be able to use the device (technological challenge) and by the perception of more attention by the medical staff. This may explain the significant dropout rate (80%) from the post-trial rehabilitation of the patients who used the device. Discussion The system was largely accepted by the patients. The results suggest that the need for information on their rehabilitation progress and the technological challenge deserves further study to make patients more autonomous in cases of continuous rehabilitation.
Collapse
Affiliation(s)
- D Pani
- DIEE – Department of Electrical and Electronic Engineering, University of Cagliari, Italy
| | - M Piga
- Rheumatology Unit, Department of Medical Sciences, University and AOU of Cagliari, Italy
| | - G Barabino
- DIEE – Department of Electrical and Electronic Engineering, University of Cagliari, Italy
| | - M Crabolu
- DIEE – Department of Electrical and Electronic Engineering, University of Cagliari, Italy
| | | | - A Mathieu
- Rheumatology Unit, Department of Medical Sciences, University and AOU of Cagliari, Italy
| | - L Raffo
- DIEE – Department of Electrical and Electronic Engineering, University of Cagliari, Italy
| |
Collapse
|
38
|
Abstract
Management of central nervous system (CNS) involvement still remains one of the most challenging problems in systemic lupus erythematosus (SLE). The best available evidence for the treatment of CNS lupus is largely based on retrospectiveseries, case reports and expert opinion. Current therapy is empirical and tailored to the individual patient. Symptomatic, immunosuppressiveand anticoagulant therapies are the main strategies for the management of CNS lupus. The choice depends on the most probable underlying pathogenic mechanism and the severity of the presenting neuropsychiatric symptoms. Thrombotic and nonthrombotic CNS disease needs to be differentiated and requires different management strategies. However, this is often challenging since many, if not most CNS manifestations, may be due to a combination of different pathogenic mechanisms and multiple CNS events may occur in the individual patient. Patients with mild manifestations may need symptomatic treatment only, whereas more severe acute nonthrombotic CNS manifestations may require pulse intravenouscyclophosphamide.Plasmapheresismay also be added in patients with more severe illness refractory to conventionaltreatment. Recently, the use of intrathecalmethotrexateand dexamethasone has been reported in a small series of patients, with a good outcome in patients with severe CNS manifestations.Anticoagulationis warranted in patients with thrombotic disease, particularlyin those with the antiphospholipid syndrome (APS). This article reviews the clinical approach to therapy in patients with CNS lupus.
Collapse
Affiliation(s)
- G Sanna
- Department of Rheumatology, Homerton University Hospital, London E9 6SR, UK.
| | | | | |
Collapse
|
39
|
Piga M, Congia M, Floris A, Gabba A, Cauli A, Mathieu A. AB0479 Musculoskeletal Manifestations Are Major Determinants of Impaired Quality of Life in Patients with Systemic Lupus Erythematosus. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Garrigues P, De Roux T, Wanono E, Mathieu A. Arthrite réactionnelle à Clostridium difficile : à propos de 2 observations et revue de la littérature. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.04.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
41
|
Porru G, Marchesoni A, Olivieri I, Scarpa R, Salvarani C, Lubrano E, D'Angelo S, Piga M, Catanoso M, Peluso R, Parsons W, Mathieu A, Cauli A. AB0731 Musculoskeletal but Not Skin Disease Activity Influence Rheumatologists Decision To Change Dmards or Biologic Therapy in Psoriatic Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
42
|
Porru G, Marras M, Piga M, Floris A, Ibba V, Marcia S, Mathieu A, Cauli A. FRI0418 Male Gender but Not HLA-B27 Positivity or Occurrence of Uveitis as Severity Prognostic Factor in Sardinian Ankylosing Spondylitis Patients. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Affiliation(s)
- E. V. Gillam
- Clinique Vétérinaire de la Côte Fleurie; Deauville France
| | - A. Mathieu
- Pool House Equine Clinic; Lichfield Staffordshire UK
| | - M. Lacourt
- Clinique Vétérinaire de la Côte Fleurie; Deauville France
| |
Collapse
|
44
|
Maruani A, Huguet G, Beggiato A, ElMaleh M, Toro R, Leblond CS, Mathieu A, Amsellem F, Lemière N, Verloes A, Leboyer M, Gillberg C, Bourgeron T, Delorme R. 11q24.2-25 micro-rearrangements in autism spectrum disorders: Relation to brain structures. Am J Med Genet A 2015; 167A:3019-30. [DOI: 10.1002/ajmg.a.37345] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2015] [Accepted: 08/12/2015] [Indexed: 01/24/2023]
Affiliation(s)
- Anna Maruani
- Human Genetics and Cognitive Functions; Institut Pasteur; Paris France
- CNRS URA 2182; Institut Pasteur; Paris France
- Department of Child Psychiatry; Robert Debré Hospital, APHP; Paris France
| | - Guillaume Huguet
- Human Genetics and Cognitive Functions; Institut Pasteur; Paris France
- CNRS URA 2182; Institut Pasteur; Paris France
| | - Anita Beggiato
- Human Genetics and Cognitive Functions; Institut Pasteur; Paris France
- CNRS URA 2182; Institut Pasteur; Paris France
- Department of Child Psychiatry; Robert Debré Hospital, APHP; Paris France
| | - Monique ElMaleh
- Department of Radiology; Robert Debré Hospital, APHP; Paris France
| | - Roberto Toro
- Human Genetics and Cognitive Functions; Institut Pasteur; Paris France
- CNRS URA 2182; Institut Pasteur; Paris France
| | - Claire S. Leblond
- Human Genetics and Cognitive Functions; Institut Pasteur; Paris France
- CNRS URA 2182; Institut Pasteur; Paris France
| | - Alexandre Mathieu
- Human Genetics and Cognitive Functions; Institut Pasteur; Paris France
- CNRS URA 2182; Institut Pasteur; Paris France
| | | | - Nathalie Lemière
- Human Genetics and Cognitive Functions; Institut Pasteur; Paris France
- CNRS URA 2182; Institut Pasteur; Paris France
| | - Alain Verloes
- Department of Human Genetics; Robert Debré Hospital, APHP; Paris France
| | - Marion Leboyer
- INSERM U955, Team 15; Faculty of Medicine; Creteil France
- Department of Adult Psychiatry; Henri Mondor-Albert Chenevier Hospitals AP-HP; Creteil France
- Fondation FondaMental; French National Science Foundation; Creteil France
| | - Christopher Gillberg
- Gillberg Neuropsychiatry Centre; Gothenburg University; Göteborg Sweden
- Saint George's Hospital Medical School; London United Kingdom
| | - Thomas Bourgeron
- Human Genetics and Cognitive Functions; Institut Pasteur; Paris France
- CNRS URA 2182; Institut Pasteur; Paris France
- Diderot Paris 7; University Paris; Paris France
| | - Richard Delorme
- Human Genetics and Cognitive Functions; Institut Pasteur; Paris France
- CNRS URA 2182; Institut Pasteur; Paris France
- Department of Child Psychiatry; Robert Debré Hospital, APHP; Paris France
- Fondation FondaMental; French National Science Foundation; Creteil France
| |
Collapse
|
45
|
Piga M, Casula L, Perra D, Sanna S, Floris A, Antonelli A, Cauli A, Mathieu A. Population-based analysis of hospitalizations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001-2012. Lupus 2015. [PMID: 26199283 DOI: 10.1177/0961203315596597] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
OBJECTIVE The objective of this paper is to evaluate hospital admissions in systemic lupus erythematosus (SLE) patients through a retrospective population-based study analyzing hospitalization data during 2001-2012 in Sardinia, an Italian region with universal health system coverage. METHODS Data on the hospital discharge records with the ICD-9-CM code for SLE (710.0) were obtained from the Department of Health and Hygiene and analyzed, mostly focusing on primary and non-primary diagnosis and Diagnosis-Related Group (DRG) code. In order to establish the significance of the annual trend for number and type of primary and non-primary discharge diagnosis, the two-tailed Cochran-Armitage test for trend was applied. In order to estimate SLE prevalence, data from administrative database and medical records were assembled. RESULTS This study included 6222 hospitalizations in 1675 patients (87% women). Hospitalizations with SLE as primary diagnosis were 3782 (58.0%) and significantly decreased during the study period. The annual number of renal, hematologic and neuropsychiatric disorders as non-primary diagnosis associated with SLE remained constant; however, their percentage increased (p < 0.0001) because of a declining number of admissions for SLE without associated diagnosis and without complications. Hospitalizations with SLE as non-primary diagnosis showed a significant upward trend in number and percentage of cerebrovascular accident (p = 0.0004), acute coronary syndrome (p = 0.0004) and chronic renal failure (p = 0.0003) as underlying primary diagnosis, while complications of pregnancy, labor and childbirth (p = 0.3375), malignancies (p = 0.6608) and adverse drug reactions (p = 0.2456) did not show statistically significant changes. Infections showed an increasing trend between 2001 and 2012 but did not reach statistical significance (p = 0.0304). After correction for hospitalization (93.8%) and survival (91.1%) rates calculated over the study period, the 2012 SLE prevalence in Sardinia was estimated to be 99.3 per 100,000 inhabitants. CONCLUSIONS While overall hospitalizations for SLE patients declined, those for cerebrovascular accident, acute coronary syndrome and chronic renal failure as underlying primary diagnosis increased during the study period.
Collapse
Affiliation(s)
- M Piga
- Rheumatology Unit, University Clinic AOU of Cagliari, Italy
| | - L Casula
- Rheumatology Unit, University Clinic AOU of Cagliari, Italy Regional Epidemiological Observatory, Department of Health and Hygiene, Sardinian Regional Government, Cagliari, Italy
| | - D Perra
- Rheumatology Unit, University Clinic AOU of Cagliari, Italy
| | - S Sanna
- Rheumatology Unit, University Clinic AOU of Cagliari, Italy
| | - A Floris
- Rheumatology Unit, University Clinic AOU of Cagliari, Italy
| | - A Antonelli
- Regional Epidemiological Observatory, Department of Health and Hygiene, Sardinian Regional Government, Cagliari, Italy
| | - A Cauli
- Rheumatology Unit, University Clinic AOU of Cagliari, Italy
| | - A Mathieu
- Rheumatology Unit, University Clinic AOU of Cagliari, Italy
| |
Collapse
|
46
|
Piga M, Casula L, Perra D, Sanna S, Floris A, Antonelli A, Cauli A, Mathieu A. AB1141 Population-Based Analysis of Hospitalizations in a West-European Region Revealed Major Changes in Hospital Utilization for Patients with Systemic Lupus Erythematosus Over the Period 2001-2012. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3545] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
47
|
Piga M, Gabba A, Figus F, Congia M, Cauli A, Mathieu A. SAT0410 Musculoskeletal Flares and Development of Hand Deformities in Systemic Lupus Erythematosus: A 5-Year Clinical and Ultrasonographic Prospective Follow-up Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Floris A, Piga M, Massa L, Vacca S, Corraine M, Vacca A, Garau P, Ibba V, Cauli A, Mathieu A. AB0542 Disease Flares in a Monocentric Cohort of Patients with Systemic Lupus Erythematosus: Incidence, Clinical and Laboratory Characteristics, Associated Factors and Treatment. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
49
|
Piga M, Figus F, Mathieu A, Prevete I, Iuliano A, Bettio S, Bortoluzzi A, Coladonato L, Brizzi G, Spinelli F, Tani C, Sebastiani G. FRI0410 Factors Associated with Early Damage Accrual in Patients with Systemic Lupus Erythematosus: 12-Month Preliminary Results from the Inception Cohort of the Multicenter Early Lupus Project. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
50
|
Sebastiani GD, Prevete I, Piga M, Iuliano A, Bettio S, Bortoluzzi A, Coladonato L, Tani C, Spinelli FR, Fineschi I, Mathieu A. Early Lupus Project – A multicentre Italian study on systemic lupus erythematosus of recent onset. Lupus 2015; 24:1276-82. [DOI: 10.1177/0961203315585817] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2015] [Accepted: 04/14/2015] [Indexed: 11/17/2022]
Abstract
Background Systemic lupus erythematosus (SLE) is an autoimmune disease with a high degree of variability at onset that is problematic for a correct and prompt diagnosis. We undertook this project with the purpose of collecting an inception cohort of Italian patients with recent-onset SLE, in order to obtain information on the main clinical and serological characteristics at the beginning of the disease. In this first report we describe the characteristics of this cohort at study entry. Methods All patients with a diagnosis of SLE (1997 ACR criteria) and a disease duration less than 12 months were consecutively enrolled between 1 January 2012 and 31 December 2013 in a multicentre prospective study. Information on clinical and serological characteristics at study entry and then every six months was collected into a specific electronic database. Statistical analysis was performed by means of the Openstat program. Results Among 122 patients enrolled (103 F) 94.3% were Caucasians. Mean age (SD) of patients at study entry was 37.3 (14.3) years, mean age at disease onset was 34.8 (14.3) years, mean age at diagnosis was 36.9 (14.3) years, and mean disease duration was 2.9 (3.9) months. The frequency of the manifestations included in the 1997 ACR criteria was as follows: ANA 97.5%, immunologic disorders (anti-dsDNA, anti-Sm, antiphospholipid antibodies) 85.2%, arthritis 61.8%, haematologic disorders 55.7%, malar rash 31.1%, photosensitivity 29.5%, serositis 27%, renal disorders 27%, oral/nasal ulcers 11.5%, neurologic disorders 8.2%, and discoid rash 5.7%. The cumulative frequency of mucocutaneous symptoms was 77.8%. At enrolment, autoantibody frequency was: ANA 100%, anti-dsDNA 83.6%, anti-SSA 28%, anticardiolipin 24.5%, anti-nRNP 20.4%, anti-beta2GPI 17.2%, lupus anticoagulant 16.3%, anti-Sm 16%, and anti-SSB 13.1%. Conclusions In this paper we describe the main clinical and serological characteristics of an Italian inception cohort of patients with recent-onset SLE. At disease onset, mucocutaneous manifestations, arthritis and haematologic manifestations were the most frequent symptoms; ANA, anti-dsDNA and complement reduction were the most frequent laboratory findings. Our data confirm that the diagnosis of SLE is a challenging one, and that SLE is a severe disease even at onset, since the majority of patients require at least a hospitalization before the diagnosis.
Collapse
Affiliation(s)
- G D Sebastiani
- UOC Reumatologia, Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy
| | - I Prevete
- UOC Reumatologia, Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy
| | - M Piga
- Cattedra e Struttura Complessa di Reumatologia, Università degli Studi e AOU di Cagliari, Italy
| | - A Iuliano
- UOC Reumatologia, Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy
| | - S Bettio
- Divisione di Reumatologia, Università di Padova, Italy
| | - A Bortoluzzi
- UO e Sezione di Reumatologia – Dipartimento di Scienze Mediche, Università degli Studi di Ferrara, Italy
| | - L Coladonato
- Dipartimento Interdisciplinare di Medicina–Sezione di Reumatologia, Università di Bari, Italy
| | - C Tani
- UO Reumatologia, Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Italy
| | - F R Spinelli
- Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Italy
| | - I Fineschi
- UOC di Reumatologia, Azienda Ospedaliera Universitaria Senese, Italy
| | - A Mathieu
- Cattedra e Struttura Complessa di Reumatologia, Università degli Studi e AOU di Cagliari, Italy
| |
Collapse
|